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Abstract
Using confocal Raman spectroscopy/microscopy, we have monitored pharmaceutical crystallisation 
'in situ' in three model (well characterised polymorphic systems) Active Pharmaceutical Ingredients 
(APIs) and one previously unstudied system where polymorphism had not being reported prior to 
this study: flufenamic acid, a Non Steroidal Non-Inflammatory Drug (NSAID); nifedipine, an anti-
hypertensive; tolbutamide, used in the treatment of type II diabetes; and imipramine hydrochloride, 
an antidepressant respectively. Constrained crystallisation from the solid amorphous state was 
utilised to kinetically trap polymorphs via the Ostwald's rule of stages. Particular emphasis was 
placed on the phonon-mode/low wavenumber region (4-400cm-1) of the Raman spectral window 
(this region provides useful information about lattice environment).
In all cases our results from the Raman experiments were complemented with similar experiments 
using Differential Scanning Calorimetry (DSC) and Variable Temperature X-ray Powder Diffraction 
(VTXRPD). To reduce data complexity, principal component analysis was deployed and found to be 
extremely effective.
In chapter two, a multi-technique study of flufenamic acid (FFA) was carried out which served as a 
groundwork for later chapters. A solid-solid transformation between two forms of FFA (forms I and 
III) was observed, due to the abrupt nature of this transition, the 'Lindemann vibrational catastrophe' 
was envisaged as a possible mechanism for the transformation.
Using FFA as a test case in chapter three, polymorphic transformations was monitored in both FFA 
forms I and III using in situ Raman spectroscopy (as well as VTXRPD) by adopting the constrained 
crystallisation approach. The approach showed excellent promise (with the XRPD patterns of FFA 
form II and one unknown form uncovered) and was further explored in later chapters using a variety 
of pharmaceutical materials.
While in chapter four, the interconversion between the different polymorphs of nifedipine was 
studied using the constrained crystallisation approach monitored using in situ Raman spectroscopy 
(together with VTXRPD and DSC), our results compared favourably well with those previously 
published in literature. We also reported for the first time the phonon-mode Raman spectral for this 
system as earlier publications focussed only on the 'traditional' fingerprint region.  
Similarly in chapter five, in situ Raman spectroscopy was also used to monitor the polymorphic 
transformations in tolbutamide (using the constrained crystallisation approach), results from the 
Raman analysis was compared with those obtained from VTXRPD and found to be in agreement. 
Thus further showing that Raman spectroscopy combined with the constrained crystallisation 
approach is a veritable tool for monitoring polymorphic transitions.
In chapter six, preliminary results (Raman/XRPD/DSC) showed for the first time that imipramine 
hydrochloride exhibits polymorphism, with the possibility of at least two new polymorphs. 
Combination of state of the art spectroscopic techniques with appropriate statistical  methods, X-ray 
powder diffraction and DSC was shown to be an extremely effective approach to investigating and 
characterising polymorphism in drugs, often using only milligram or sub-milligram sample 
quantities.
Lastly in chapter seven, the novel technique of Transmission Raman Spectroscopy (TRS) was 
employed in carrying out a quantitative study of polymorphic content in a model pharmaceutical 
formulation and the results obtained compared with those from traditional backscattering geometry. 
The transmission method is shown to provide a true bulk measurement of the composition, being 
unaffected by systematic or stochastic sub-sampling issues that can plague traditional 
backscattering geometries.
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1   Introduction
1.1  Polymorphism
A large number of drugs are made from organic compounds which exists in different solid forms 
e.g. as crystalline or non-crystalline solids. A large number of these drugs are made available for use 
as oral dosage forms, the most popular being tablets and capsules. 
The solid-state properties of a drug that is expected to be marketed as a solution may also be 
required to be known prior to formulation. In fact, the existence of any drug irrespective of the form 
by which it is finally administered is affected by the properties of the solid form, it is therefore 
important to find and select the solid form of any drug product with the optimal characteristic at the 
very early stages of drug development, in order to prevent unwanted 'surprises' in the later stages of 
development or after the drug has been approved for usage.
More so, pharmaceutical processes such as drying, grinding, compression and granulation can 
induce molecular changes in these materials, hence a good knowledge and understanding of the 
likely structural changes that a pharmaceutical material could likely undergo during the preparation 
of a new drug formulation is also very important. For example, anhydrous caffeine has been 
reported to change from its metastable form I to the stable form II by grinding.1
Polymorphs are materials with the same chemical (molecular) composition, but with different 
crystal structures, and therefore different physical properties, including melting point, colour, 
solubility, bioavailability etc.2 Characterising polymorphs is an essential aspect of drug 
development in order to ensure safe and efficacious formulation and delivery, and is a regulatory 
requirement in getting a new medicine onto the market and thereby to patients.2
The type of formulations used during the various stages of drug development also determines the 
final properties of the drug product: for example when suspensions are used, particle size must be 
controlled as this can affect bioavailability. Also the solid-state properties of both the active 
ingredient and the excipient must be closely monitored for their chemical compatibility, which is 
why drugs that are expected to be poorly soluble are produced as salts while others are synthesised 
as hydrates for stability.
The relevance of polymorphism in the pharmaceutical industry cannot be over emphasised. This is 
partly due to the increased economic pressure faced by pharmaceutical companies, and the greater 
awareness of the effect that polymorphism may have on the bioavailability, manufacturability and 
stability of the drug product, as was recently evident by the recent withdrawal of neupro (a 
rotigotine patch used in the treatment of Parkinson's disease) from the market.3 
The discovery of an unexpected levels of crystallisation on the surface of neupro patches resulted in 
a catastrophic experience for the manufacturer (UCB). Another example was when Abbott 
laboratories antiretroviral drug ritonavir was unceremoniously pulled from the shelves due to 
heterogeneous nucleation on a structurally related compound.4
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Hence concerted efforts are made in the early stages of formulation of a drug product to isolate the 
polymorph with the optimal characteristics (most thermodynamically stable polymorph) under 
ambient conditions,5 so as to prevent any unexpected transformation of the final drug product during 
or after manufacturing.
Since different polymorphs will possess different inter- and intra-molecular interactions, for 
example, hydrogen bonding sequences and Van der Waals forces, they will be expected to have 
different free energies and hence different physical properties such as solubility, chemical stability, 
melting point, density, etc.6
Solvates are obtained when solvent molecules are incorporated in the crystal lattice in a 
stoichiometric or non-stoichiometric way,5 hydrates, where the solvents in this case is water, if non 
volatile molecules play the same role, the solids are called co-crystals.6 While amorphous solids are 
defined as non-crystalline solids. They is a growing interest in studying non-crystalline solids, as 
studies have shown that the amorphous state can be an intermediate in some crystals prior to crystal 
transformations.6  In this discussion the term 'polymorph' will only be used to refer to compounds 
that have similar chemical composition but different structural forms.
  1.2   Relevance of solid state properties
Different solid forms have diverse physical and chemical properties that may significantly govern 
the performance of an active pharmaceutical ingredients and hence affect the integrity and efficacy 
of the final drug product.6,7. 
Examples of these properties are listed in Table 1 below;
Table 1. Physical properties that differ among various solid forms. Modified from8
__________________________________________________________________________________________________________________________________________
Packing properties             Unit cell volume (crystalline forms only), density,        
                                           refractive index, hygroscopicity, hydrogen bonding.
Thermodynamic                 Melting point, enthalpy, entropy, free energy, solubility.
properties
Spectroscopic                     Bonding type, lattice environment, electronic transitions, colour.
properties                             
Kinetic properties              Dissolution rate, rates of solid state reactions, stability.
Surface properties             Surface free energy, inter facial tensions, crystal habit, contact angles.
Mechanical properties       Hardness, tensile strength, compactibility, tableting
                                           flowability.
2         
The difference in the mechanical properties between polymorphs can affect processing behaviour, 
which is the case with paracetamol polymorphs9, where form II is suitable for direct tablet 
compression, but form I needs to be mixed with binding agents prior to compression.10
Polymorphs I and II of sulfamerazine have also been reported to show different tableting 
properties,11 as well as different forms of theophylline.12 The performance of the drug in the human 
body can depend on the solid form, if solubility and dissolution rate are dependent on the solid state 
of the API. Well known examples have been found in cases involving anhydrous and dihydrate 
forms of carbamazepine, with the dihydrate having a higher absorption rate in vivo.13,14 Also in 
ritonavir, where the metastable form I is more soluble, hence more bioavailable than the stable form 
II.15
The aim of this project, is to investigate the use of modern automated Raman spectroscopic methods 
(including data analysis approaches) for polymorphic screening and characterisation (with the 
Raman analysis complemented with other techniques such as X-ray Powder Diffraction (XRPD), 
Differential Scanning Calorimetry (DSC), solid state Nuclear Magnetic Resonance spectroscopy 
(NMR) and Scanning electron Microscopy (SEM) ). This will involve in situ monitoring of 
pharmaceutical crystallisation using the constrained crystallisation approach (slow heating of the 
amorphous phase/form). Raman scattering is achieved when light is scattered inelastically, when a 
laser beam is used to irradiate a sample (in this case a pharmaceutical ingredient), the scattered 
radiation produced by the Raman effect contains valuable information about the energies of 
molecular vibrations and rotations, and these are directly related to the particular atoms or ions that 
the sample is comprised of, the chemical bonds connecting them, the symmetry of their molecular 
structure and the physico-chemical environment where they exist. In order words Raman 
spectroscopy can be employed to fingerprint different solid forms. Thus Raman spectroscopy is a 
unique technique for differentiating amongst the different polymorphs of the same compound as 
well as those of different compounds. Raman spectroscopy has the advantage of speed, no need for 
sample preparation and in this study we will focus on the low wave number region (4-400cm-1) 
where inter-molecular vibrations are believed to take place. Here at the University of Nottingham, 
we have a modern state of the art Raman system (based in the university's nanocentre), a confocal 
Horiba-Jobin-Yvon LabRAM system (Horiba-Jobin-Yvon Ltd Middlesex U.K.), it has four different 
laser excitation capabilities i.e. UV (325nm), NIR (785nm), red (660nm) and the green laser 
(532nm).
It has a motorised stage that can move in the x, y and z directions and can be used to carry out fast 
and extensive mapping (using the SWIFT and DUOSCAN modes) and depth profiling of various 
samples including pharmaceuticals such as tablets.
It can be automated and can be fitted with a hot-stage and used to carry out variable temperature 
experiment. It is also equipped with two separate detectors, a CCD for regular Raman analysis and 
an EMCCD for fast mapping.
Overleaf (figure 1) is a picture of the Raman system at the Nottingham Nanotechnology and 
Nanoscience Centre.
A research group that also does in situ Raman spectroscopic analysis with data analysis approaches, 
is that based at the University of Otago, New Zealand, which comprises of Keith Gordon, Thomas 
Rades and Clare Strachan. They have done extensive research on the topic of polymorphic 
screening using Raman as well as NIR (Near infra Red) spectroscopy16,17. They have also done 
studies on crystallinity and the amorphous solid state (examples include their quantitative study of 
the polymorphic mixtures of ranitidine hydrochloride using Raman spectroscopy, NIR and XRPD 
and their study of the formation and stability of amorphous ranitide hydrochloride prepared by cryo-
milling). But more recently their work has focused on the use of terahertz pulsed 
spectroscopy/imaging in studying pharmaceutical materials. It is worth mentioning though, that 
Raman spectroscopy tends to be used in a chemical engineering context rather than pharmaceutics.
3
As part of this study, we will also compare the conventional Raman spectroscopy with the new 
technique of transmission Raman spectroscopy (TRS, here Raman signal is collected on the side of 
the sample, in traditional Raman, signal is scattered from the surface of the sample) in quantifying 
polymorphic contents of a pharmaceutical formulation.
Figure 1: Picture of the Raman system at the Nottingham Nanotechnology and Nanoscience Centre
1 = laser source, 2 =sample stage, 3 = illumination source
4
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1.3   Polymorphs/Solid state screening
A thorough knowledge of the physical/chemical properties of a compound offers varied options 
during the selection of the most suitable crystal form for future pharmaceutical development.4 But 
more importantly, it prevents unexpected surprises during later stages of drug development, as 
mentioned earlier in the cases of neupro and ritonavir.
During solid state screening, different solid forms e.g. polymorphs, solvates and hydrates are 
identified and characterised as a knowledge of as many possible forms is needed. The optimal form 
is then chosen for further chemical and pharmaceutical development.6 The thermodynamically 
stable form is then isolated which in the absence of solvents and humidity is not expected to 
transform into another polymorphic form.6
Aside from the the traditional thermodynamically stable form, hydrates are also very popular 
components of the final dosage form, as they are often the thermodynamically stable form at 
ambient conditions.18
1.4   Enantiotropism versus monotropism; Burger and Ramberger rules
Phase transitions in solids can either be thermodynamically reversible or irreversible: Polymorphic 
modifications which transform reversibly without passing the liquid or gaseous state, are termed 
enantiotropes. If the modifications are not interconvertable under the same conditions the system is 
monotropic.17
Lehmann, in 1888, coined the terms enantiotropism and monotropism to distinguish two different 
types of polymorphic behaviour.6 Two types of graphs are commonly used to describe the 
thermodynamic behaviour of polymorphs, namely, energy-temperature diagrams and pressure-
temperature diagrams.6 In this study, emphasis will be placed only on the former (as the study will 
focus mainly on the temperature dependence nature of polymorphic transitions).
Energy-Temperature Diagrams
Energy-temperature diagrams were first introduced in crystallography by Burger et al in 1937.6 
These authors used schematic plots of internal energy (U) and Helmholtz free energy (A) versus 
temperature (T) to represent the phase transformations in crystalline solids. They argued that the 
enthalpy of crystalline solids under normal pressure conditions has negligible contribution from 
pressure-volume energy (PV).6 Therefore, for crystalline solids at ambient pressure:
H = U + PV ~ U    
G = H – TS ~ U -TS = A (H=enthalpy, G=standard free energy, T=temperature and S=entropy)
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To further understand the two concepts, let us consider a system with two polymorphs, I and II 
(with II being more stable at absolute zero temperature), for this system two different energy-
temperature diagrams can be drawn to explain these concepts (enantiotropism and monotropism), 
the diagrams are  as shown in figures 2a and 2b:19
                     H= Enthalpy, G=free Energy, Mp=melting point, Tp=transition point
                                     Figures 2a and 2b: Enantiotropism versus Monotropism
Figure 2a represents an enantiotropic system: the defining feature for such a system is the existence 
of a transition point (Tp) below the melting point of both polymorphs. In the figures 2a and 2b, the 
melting point of a polymorph can be defined as the temperature at which the free energy isobar of 
the polymorph intersects the free energy isobar of the liquid. 
However, the thermodynamic transition temperature is defined as the temperature at which the free 
energy isobar of polymorph I intersects the free energy isobar of polymorph II, thus at Tp both 
polymorphs have equal free energy, i.e., G(I) = G(II) and consequently are in equilibrium with each 
other. Below Tp, polymorph II is the stable solid phase because the free energy of II is lower than 
that of I, i.e., G(II) < G(I). Consequently, below Tp, polymorph I can undergo spontaneous 
exothermic transformation into polymorph II. Above Tp, polymorph I is the stable solid phase 
because its free energy is lower than that of polymorph II, i.e., G(I) < G(II). Therefore, above Tp 
polymorph II can undergo spontaneous endothermic transformation into polymorph I.
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Figure 2b represents a monotropic system. In general, in monotropic systems, solid-solid 
transformation occurs at a temperature that provides the system with sufficient thermal energy to 
cross the activation energy barrier, thus the transition point Tp in a monotropic system is a virtual 
transition point, because it lies above the melting point of both polymorphs. Hence by definition, a 
pair of polymorphs has a monotropic relationship if one of the polymorphs is always stable below 
the melting points of both polymorphs.6
 As illustrated in figures 2a and 2b, if the free energy of polymorph I at all temperatures is below the 
melting point of both polymorphs, thus polymorph II can undergo a spontaneous transformation 
into polymorph I. For a monotropic system, this transformation is thermodynamically feasible at all 
temperature, because G(II) < G(I) at all temperatures.
More recently, Burger and Ramberger20 developed rules (heat of transition and heat of fusion) 
which states that in the case of enantiotropism the transition of two polymorphic modifications is 
endothermic, whereas for monotropic forms it is exothermic.
Heat of transition rule: This rule states that if an endothermic phase transition is observed at a 
particular temperature (referred to as the experimental or kinetic transition temperature), the 
thermodynamic transition point lies below this temperature. Consequently, we can conclude that the 
two polymorphs are enantiotropically related.6
If an exothermic phase transition is observed at a particular temperature (experimental or kinetic 
transition temperature), there is no thermodynamic transition point below this temperature. This can 
occur either when the two polymorphs are monotropically related or when the two polymorphs are 
enantiotropically related and in addition have their thermodynamic transition temperature higher 
than the experimentally observed transition temperature.
Heat of fusion rule: This rule states that if the higher melting point polymorph has the lower heat of 
fusion then the two polymorphs are enantiotropic, otherwise they are monotropic.6 Often, the rate of 
polymorphic transition is too slow to allow for an accurate measurement of the heat of transition, in 
which case the heat of fusion rule may be applied. This rule is based on the assumption that the heat 
of transition can be approximated by the difference between the heats of fusion of the polymorphs.6
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1.5    Ostwald Rule
In 1897, a paper titled 'Studien ueber die Bildung und Umwandlung fester Koerper' (Studies of the 
formation and transformation of solid substances)21 was published by Wilhelm Ostwald. The paper 
discussed the role of seeding of supercooled melts and supersaturated solutions, with particular 
emphasis on how small a quantity of seed crystal was needed to bring about crystallisation.
In conclusion, the author propounded what is now commonly known as Ostwald's rule or Ostwald's 
law of stages: 'When leaving a given state and in transforming to another state, the state which is 
sought out is not the thermodynamically stable one, but the state nearest in stability to the original 
state'.22
This implies that, in a crystallisation from the melt or from solution, the solid first formed will be 
that which is the least stable of the polymorphs, the one with the largest Gibbs free energy.20
This rule has been used extensively to explain why and how the process of crystallisation from the 
melt or from solution progresses, until very recently when the general applicability of the rule was 
queried by the discovery of a little known phenomenon, namely that it is possible to convert a stable 
polymorph to a less stable one by grinding.23-26
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1.6    Characterisation of polymorphic systems
Various analytical techniques are available for the characterisation of the solid phase analysis of 
pharmaceutical materials, these includes thermal methods such as Differential Scanning 
Calorimetry (DSC) and themomicroscopy, vibrational techniques e.g. Infra red and Raman 
spectroscopy. Solid state Nuclear Magnetic Resonance (NMR) spectroscopy, X-ray diffraction 
(single crystal and powder) etc.
The method of choice would depend on factors such as: the nature of the material to be analysed, 
key parameters one needs to determine and the extent to which these parameters are to be 
investigated. Usually it is advisable to use two or more complementary methods to obtain a reliable 
knowledge of the forms.27
For the work described below five different analytical methods were employed: namely  DSC 
(standard and temperature modulated), X-Ray Powder Diffraction (XRPD), Raman spectroscopy 
(traditional and transmission geometries), thermomicroscopy and solid state NMR.
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1.6a     Differential Scanning Calorimetry (DSC)
Differential scanning calorimetry is very useful technique for measuring heat effects (exothermic 
and endothermic events) associated with phase transitions and chemical reactions as a function of 
temperature.
In DSC the difference in heat flow to the sample and a reference at the same temperature, is 
recorded as a function of temperature. The reference is an inert material such as alumina, or an 
empty aluminium pan .
The temperature of both the sample and reference are increased at a constant rate. Since the DSC
is at constant pressure, heat flow is equivalent to enthalpy changes (ΔH). DSC equipment are 
calibrated using the indium standard or more recently, sapphire prior to use. The advantages of DSC 
includes speed, minimal sample requirement and nowadays it is automated, but it is a destructive 
method of analysis.
Applications
DSC can be used to determine
1. Glass transition 
2. Melting temperature 
3. Heat of fusion 
4. Percent crystallinity 
5. Crystallization kinetics and phase transitions 
  
                                     Figure 3: A typical DSC scan for an amorphous material
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Types of DSC
Based on mechanism of operation DSC can be classified into two types.
1. Heat flux DSC 
2. Power Compensated DSC 
Heat Flux DSC
In  heat flux DSC, both the sample and reference material are heated together in the same furnace, 
when  the  furnace  is  heated,  the  heat  is  transferred  to  both  sample  and  reference  pans  via  a  
thermoelectric disk. A temperature difference exists between sample and the reference owing to the 
heat capacity of the sample.
Power Compensated DSC
In power  compensated  DSC, the  sample  and reference  pan are  in  separate  furnaces  heated  by 
separate heaters. Both the sample and reference are maintained at the same temperature and the 
difference in thermal energy required to maintain them at the same temperature is measured and 
plotted as a function of temperature or time. 
                                Figure 4: Schematic diagram of the two types of DSC28
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1.6b     X-Ray Powder Diffraction
X-ray powder diffraction is the 'gold standard' when it comes to the structural elucidation of 
different solid forms including APIs. XRPD patterns can be compared with calculated X-ray 
diffraction patterns obtained from crystallographic databases such as Cambridge Crystallographic 
Data Centre database (CCDC), from which useful information apart from unit cell dimension, such 
as point group symmetry and Bravais lattices can be obtained, leading to elucidation of crystal 
structures that where previously unknown. Below in table 2 is a list of the seven crystal systems and 
their corresponding Bravais lattices and symmetries, modified from.29
Table 2: The seven crystal systems and their corresponding Bravais lattices symmetries
                                                                  Non-centrosymmetric                               Centrosymmetric point
                                                                               point groups                                          groups
                   Bravais       Characteristic      Enantiomorphous   Non-enantiomorphous    Non-enantiomorphous
System       lattices         symmetry                    
                                                                          
Cubic          P I F           4 triads equally             23, 432              43m                                    m3, m3m
                                     inclined at 109.47O   
Tetragonal  P I              1 rotation tetrad             4P, 422               4, 4mmP , 42m                   4/m, 4/mmm 
                                      or inversion tetrad   
Ortho-         P I C R      3 diads equally              222                     mm2P                                                     mmm        
rhombic                        inclined at 90O   
Trigonal      P R             1 rotation triad or         3P                       3mP                                    3,3m
                                       inversion triad
                                      (= triad + centre
                                      of symmetry)
Hexagonal  P                1 rotation hexad or        6P, 622              6, 6mmP, 6m2                    6/m, 6/mmm                 
                                      inversion hexad
                                     (= triad + perp.
                                      Mirror plane)
Monoclinic  P C           1 rotation diad or           2P                                      mP                                     2/m   
                                     inversion diad
                                     (= perp. mirror plane)
Triclinic       P               none                               1P                                                              I   
 __________________________________________________________________________________________________________________________________________
Crystalline materials were discovered to interact with X-ray wavelengths in a three-dimensional 
format similar to the spacing of planes in a crystal lattice leading to the use of X-ray diffraction as a 
technique for the study of crystal structures and atomic spacing.30
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When an X-ray beam hits a sample and is diffracted (Debye-Scherrer geometry), we can measure 
the distances between the planes of the atoms that constitute the sample when conditions satisfy 
Bragg's law  (Bragg's law equates the angle (θ) between the incident and the scattered ray to (d) the 
spacing between the crystal planes and the wavelength (λ) of the radiation  nλ = 2dsin(θ).  
The characteristic set of d-spacings generated in a typical X-ray scan provides a unique 
"fingerprint" of the material present in the sample. When properly interpreted, by
comparison with standard reference patterns and measurements, this "fingerprint" allows for 
identification of the material.
While in the Bragg-Brentano method, the instrument uses a line focus x-ray tube, collimators and 
soller-slits are then used to define the divergence beam. On the diffracted beam side a (or graphite 
monochromator) in combination with a scintillation counter defined the energy window of the 
detected radiation.30
A receiving slit together with the step width of the diffractometer scans define the resolution of the 
patterns. The diffractometer uses a symmetrical beam and is operated in θ/2θ mode for the sample 
and detector rotation.
XRPD can be used to analyse mixed samples e.g. a mixture of two different polymorphs, it is fast 
and non-destructive and can be adapted for in-situ structural determination.
But it disadvantages includes; most modern diffractometers are expensive and XRPD analysis 
require large amounts of sample.           
13
1.6c     Nuclear Magnetic Resonance Spectroscopy
Solid state NMR is now routinely used in pharmaceutical research for structural elucidation of 
compounds, investigating the chirality of drug substances, protein studies e.t.c.31
When a nucleus (of spin, I=1/2) is place in a magnetic field (figure 5 below). It spins on its axis. In 
the presence of a magnetic field, this axis of rotation will precess around the magnetic field; The 
nucleus can align with the magnetic field of strength BO in only 2I+1 ways, either re-enforcing or 
opposing BO. The magnetogyric constant g relates the spin number I for a particular nucleus to the 
magnetic moment m; for a single nucleus with I = ½ and positive g, only one transition is possible 
between the two energy levels; NMR uses information about such transitions and interprets it in 
terms of chemical structure.31
                                   Figure 5: A nucleus precessing in a magnetic field
Cross polarization with magic angle spinning (CPMAS) is deployed when analysing pharmaceutical 
materials with solid state NMR, which entails spinning the sample (usually at a frequency of 1 to 
70khz) at the unique magic angle θm (ca. 54.74O, where Cos2θm = ⅓) with respect to the magnetic 
field, this has the advantage of narrowing the usually broad lines, thus increasing the quality of 
resolution for better identification and analysis of the spectrum.32,33
NMR spectroscopy is highly selective and quantitative, it requires minimal sample preparation but 
it is very expensive method due to cost of instrumentation.
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1.6d    Raman Spectroscopy
a) Conventional/Traditional Geometry
When a sample is irradiated by a monochromatic radiation, the incident light is scattered 
inelastically in all directions: some are absorbed while some are reflected.
The incident photons promote the potential energy of a molecule to a higher energy virtual state, 
most then relax to the ground state with the emission of photons unchanged in frequency, but also, a 
small amount of radiation that is scattered at some different wavelength (Stokes and Anti-Stokes 
Raman scattering, approximately only 1 x 107 of the scattered light is Raman). It is the change in 
wavelength of the scattered photon which provides the chemical and structural information. 
The uses of Raman spectroscopy includes detection of counterfeit and adulterated pharmaceutical 
products, mineralogy studies, biodiagnostic studies etc.34 But in this study particular emphasis is on 
the phonon region (low wave number region of the the spectra), where absorption of radiation by 
the crystal lattice of samples is believed to occur.
                      Figure 6: Schematic representation of the theory of Raman Spectroscopy
Raman spectroscopy is highly specific, fast and requiring no sample preparation. It can be carried 
out in solution, works with both liquids and solids, can be easily automated. It is expensive and 
because of the weak nature of Raman signal, its detection requires a sensitive and highly optimised 
instrumentation.
15
b) Transmission Geometry (Transmission Raman Spectroscopy, TRS)
Unlike conventional/traditional Raman spectroscopy, where the signal is collected back-scattered 
from the sample surface, a TRS signal is collected on the opposite side of the sample35 (see figure 
836).
The additional advantages of the TRS approach over conventional Raman spectroscopy includes its 
ability to non- invasively probe the bulk content of turbid samples, including the elimination of sub-
sampling problem and the effective suppression of surface fluorescence, which have not been 
recognised and exploited until recently.37,38
Other obvious advantages of TRS of traditional Raman spectroscopy includes: ability to provide 
bulk averaged information on the composition of dosage forms and its ability to penetrate coatings 
and capsule shells.
These new characteristics features in Raman analytical capability is particularly useful in areas such 
as non-invasive pharmaceutical concentration measurements and in vivo disease diagnosis.39
                            Figure 8: Schematic diagram of transmission Raman spectroscopy36
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1.6e    Thermomicroscopy
Thermomicroscopy (also known as hot stage microscopy and fusion microscopy) allows the direct 
observation of small samples as they are heated or cooled in a micro-furnace, or hot stage, that is 
placed on the specimen stage of a polarizing light microscope6 (see figure 10).
It is the least commonly used technique for the characterisation of the solid-state properties of 
organic compounds, particularly the polymorphism of pharmaceutical compounds. Various authors 
have published books40,41 and papers42-47 on this unique technique. 
 Figure 9: Microscope heating stage (Linkam) mounted on the rotating stage of a polarizing light   
         microscope in the Laboratory of Biophysics and Surface Analysis, School of    
         pharmacy, University of Nottingham
Apart from complementing other thermal methods of analysis such as differential scanning 
calorimetry, differential thermal analysis and thermogravimetric analysis by providing a rapid and 
non-ambiguous method to interpret thermograms,6 thermomicroscopy provides highly useful 
information about thermally induced events, such as melting, crystallisation, sublimation, 
desolvation and polymorphic transformations. Major drawback associated with thermomicroscopy 
include: image interpretation and limited chemical identification. 
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1.7   Data handling using principal component analysis
Principal component analysis (PCA) is a commonly used multivariate statistical technique for 
elucidating patterns in data of high dimension. One of its characteristic feature is the reduction of 
dimensionality in a given data set while keeping as much as possible of the variation originally 
present.48-50
PCA has been extensively deployed in this study because of the large volume of different data sets 
generated from the multiple techniques used in the probing of polymorphic behaviour in the 
pharmaceutical materials examined in this project.
The Raman spectra and x-ray patterns obtained were subjected to PCA analysis using 'PCA 
packages' within the 'R' programming suite. Raw data (variance-scaled and mean-centred before 
analysis) were used.
Analysis of the scores and loading for the most important principal components (PCs), as 
determined from percent variance plots, were used to investigate changes in the spectral features of 
the Raman data, as well as variations in the x-ray patterns.
This statistical approach proved to be very useful in this study as it helped to reduce data 
complexity and also served as a veritable tool in elucidating the different polymorphic transitions 
taking place in the systems that were studied.
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1.8  General Introduction
Interest in polymorphism and the solid state properties of drug molecules have increased 
significantly in recent times, particularly in the pharmaceutical industry; apart from being a 
regulatory requirement for drug manufacturer's to perform  polymorphic screening during  the 
early-stage of drug development, a good knowledge of the physico-chemical properties of the 
various polymorphs of a drug would guarantee product quality and effectiveness.
As a result polymorphs and all other solid forms including amorphous forms, solvate and hydrates 
have come under intense scrutiny by regulatory bodies and agencies, and with the renewed 
relevance of polymorphism, polymorph screening has been moved to a much earlier stage in the 
drug development process.51
There are several techniques used for inducing polymorphic transformations e.g. Seeding,52 addition 
of soluble additives,53-57 templating,58 solvent control,59 mechanical grinding,60,61 using supercritical 
fluids,62-65 laser induced nucleation,66,67 high-throughput screening68-74 e.t.c.
While methods of polymorphic analysis includes X-ray diffraction (single and powder), DSC, 
Raman and Infra-Red (IR) spectroscopy, thermal microscopy/gravimetry e.t.c., of all these methods, 
single-crystal X-ray diffraction is the most definitive, albeit it has the disadvantage of the need to 
find the 'perfect' single crystal which in most cases is very difficult to obtain.
The best approach that is normally used in monitoring and analysing polymorphic transition is to 
use two or more complementing methods with each method offering similar perspective of the 
entire process.
Current state of the art polymorph screening methods can employ as little as 100 mg of sample (and 
a time-scale of days/weeks) for a thorough solution-state screen.75 Reducing sample size and 
experimental time requirements has the potential to enable very early-stage screening of the solid-
state properties of new drug molecules, and lead to a more efficient drug development pipeline. 
Traditional hot-stage optical microscopy methods for investigating polymorphism can use 
microscopic (sub-milligram) amounts of sample,76 but do not provide quantitative data for 
characterisation, patent applications, etc.  
Methods to probe crystal structure or local molecular environment (as opposed to internal molecular 
structure) are necessary to characterise polymorphs, including X-ray single crystal diffraction, X-
ray powder diffraction, thermal methods, and, more recently, THz spectroscopy.77 
THz spectroscopy relies on detectors which are sensitive to very low wavelength infra-red radiation, 
including bands arising from inter- (rather than intra-) molecular vibrational (phonon) modes. The 
technology for detectors with appropriate low wave number sensitivity has only recently been 
developed.
In principle, Raman spectroscopy can offer similar phonon-mode information. Because Raman 
spectra are measured as a shift with respect to an incident radiation (rather than directly measuring 
the emitted radiation as per THz spectroscopy) conventional CCD detectors can be used, which 
significantly simplifies the experimental set-up. 
To date, a very limited number of studies in any application area have been reported using phonon-
mode Raman spectroscopy, and of these we are aware of only one report of the application of this 
technique to polymorphism in pharmaceuticals.78
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We report here some early results which indicate phonon-mode Raman spectroscopy/microscopy 
can be a very powerful tool in investigating and characterising polymorphism in pharmaceuticals, 
while requiring very little sample (mg or less).
Spectra can be recorded in a matter of seconds or less on a typical modern Raman 
microscope/spectrometer, including bands due to both inter- (10–400 cm-1) and intra-molecular 
vibrations (400–4000 cm-1). A wealth of useful chemical information can therefore be readily 
accessed. The intermolecular phonon-mode vibrations are typically several times more intense than 
the conventional intramolecular vibrations.
For an amorphous material the intermolecular vibrations are not quantised, and thus at low wave 
number a broad distribution of vibrational energies ensues, whereas for a crystalline material 
quantisation of phonon-modes leads to a series of sharp peaks, the positions of which depend 
strongly on the crystal structure. Different solid forms (polymorphs, amorphous, and salts) can 
therefore be readily distinguished.
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2.0   Polymorphism in Flufenamic Acid
2.1   Analysis and mechanistic study of a solid-solid transformation 
Abstract
 A solid-solid transformation between two polymorphs of Flufenamic Acid (FFA), namely forms I 
and III was monitored and analysed as part of a study into the rich polymorphic system of FFA. 
Initial results showed that FFA form III transforms to form I upon heating,with no region of co-
existence of the two forms during the transformation.
The said transition was monitored using DSC (differential scanning calorimetry) and in situ 
confocal Raman microscopy/spectroscopy complemented with variable temperature X-Ray Powder 
Diffraction, while solid state NMR spectroscopy was used to distinguish between the two forms: 
DSC analysis showed that the transition occurred around 104°C, while results obtained from the 
Raman in situ experiment and VTXRPD indicated that the transformation was obtained at 114°C 
and 117°C respectively, the vibrationally driven nature of the transition was suggestive of a 
mechanism similar to the 'Lindemann melting theory'.
2.2   Review of relevant literature
Flufenamic acid (FFA), a potent non-steroidal anti-inflammatory drug (NSAID) with analgesic 
properties  is used in the treatment of rheumatoid arthritis and osteoarthritis36,51. FFA, systematic 
(IUPAC) name, 2-[[3-(Trifluoromethyl)Phenyl] Amino] Benzoic acid belongs to a family of 
analgesics which also includes Mefamic and Niflumic acids, known as the fenamates.11
It is a crystalline powder, with its colour ranging from white to yellow, it has a molecular weight of 
281.22991g/mol and a molecular formular, C14H10F3NO2.
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Krc,80 in 1976 had suggested the possibility of FFA having up to seven or more different 
polymorphs. In the paper the melting points of FFA forms I and III was estimated to be 134°C and 
126.5°C respectively. Form I  was reported to be the stable form above 42°C (transition temperature 
between forms I and III), while form III is the stable form below 42°C. Forms I and III are 
enantiotropically related to each other.81
        
Various other authors have published on the topic of polymorphism in flufenamic acid,82-84 
thermodynamic properties of flufenamic acid and the fenamates,85,86 crystal structures and 
spectrocopic properties of flufenamic acid,87-94 as well as the use of Raman 
spectroscopy/microscopy in characterizing the organic solid state and polymorphs.95-120
Of particular importance to this study is the reported transition temperature between the two forms 
of flufenamic acid, namely I and III, which was estimated to be 42°C by Krc80 and 39°C by Yuerong 
et al.90. While these values where obtained using either solution mediated polymorphic 
conversions80 or in-situ Raman spectroscopy (variable temperature) of a slurry of FFA,90 the present 
study aims to estimate a transition temperature between these two polymorphs in the solid state and 
in the absence of solvents. Also the study will compare newly available phonon-mode Raman 
analysis (which has not being previously reported prior to this study) with other methods for 
characterising model polymorphic system i.e. Flufenamic acid, and see how many forms of FFA can 
be isolated.
                                      Figure 2.1: Molecular structure of Flufenamic acid
22
2.3   Experimental
2.3.1  Materials  
Flufenamic acid was purchased from Sigma-Aldrich Dorset UK. The as-received sample was 
shown by comparison of its XRPD pattern with the reported crystal structure by Krishna Murthy et 
al.87 to be form I. Pure form III was prepared by simple evaporative crystallisation from propanol 
and identified by comparison of the XRPD pattern with the reported crystal structure by 
McConnell.91
2.3.2  DSC Analysis
DSC analysis was carried out using a a DSC 2920 Differential Scanning Calorimeter (manufactured 
by TA Instruments LTD. Leatherhead UK) after previously calibrating the calorimeter using the 
indium standard.
 Approximately 4mg of the sample was accurately weighed into hermetically sealed pans, and 
heated at various heating rates (i.e. 1, 2, 5, 10, 20, 25, 50°C) and similar cooling rates  using both 
the standard and temperature modulated modes of the instrument. FFA form III was also subjected 
to the same analysis as form I.
The as received sample was also cooled isothermally for fifteen minutes over a temperature range 
of between -15 to -40°C and DSC (standard) experiments were carried out on all the cooled 
samples. 
          
2.3.3  Ball milling experiments
100mg of both forms I and III weighed and ball-milled (dry) using the Retsch MM 400 Mill,  at 
30Hz over various times ranging from 30 minutes to 3 hours. The new samples resulting from the 
milling were also analysed by DSC (standard and temperature modulated).
2.3.4  Solubility and solvent drop milling experiments 
Subsequently a basic solubility assay was carried out on both forms using solvents such as acetone, 
chloroform, methanol, methylated spirit, propanol, toluene, water and xylene in order to ascertain 
the insolubility of FFA in water and the solubility of FFA in a range of solvents.
All solvents used in the study were purchased from Fisher Scientific (UK) Limited, Bishop 
Meadow Road, Loughborough. Chloroform, methanol, and methylated spirit were procured as 
HPLC grade while ethanol, toluene, xylene and propanol were supplied as analytical grade. 
Slow evaporation experiments were also carried out on both forms: saturated solutions of the 
samples were prepared using the solvents above and left to slowly evaporate in a watch glass under 
ambient conditions.
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After the solubility experiments, 100mg of  both FFA forms I and III were weighed and milled 
(using the Retsch MM 400 Mill) with two drops, approximately 2ml (from a pipette) of each 
solvent mentioned above and all the resulting samples from the milling experiment was analysed 
using DSC (standard and temperature modulated) and XRPD.
2.3.5  XRPD     
In order to characterise the two forms i.e. FFA I and III, XRPD patterns were collected on a Bruker 
D8 diffractometer system (Bruker AXS, Madison, WI, USA), operating in a Debye-Scherrer 
geometry, at a wavelength (λ) of 1.54059Å, 40kV voltage, and a current of 40mA, using a LynxEye 
detector, samples were contained in 0.7mm borosilicate capillary tubes (Capillary tubes Ltd. UK). 
For the variable temperature experiment involving the heating of FFA III, a small amount of the 
sample was melted on a glass slide mounted on a linkam hotstage ((Linkam Scientific Instrument 
Ltd, Surrey U.K), the resulting molten liquid was drawn into a  0.3mm borosilicate capillary tube. 
The sample was heated using a Cryostream plus controller (Oxford Cryostreams Ltd. Hanborough 
Oxford OX29 8LN) at 3°C/minute from -10°C to 141°C and patterns were collected at each 
temperature step (overall accumulation time of 8 minutes) at a scan time of 0.3 second.
2.3.6  Solid-state NMR
Solid state NMR analysis of the FFA samples was carried out using the Varian Infinity Plus 
Spectrophotometer (at 300MHz using 7.04 Tesla magnet), manufactured by Chemagnetics, 2555 
Midpoint Drive Fort Collins CO. 80525 USA., both samples were homogenised with a mortar and 
pestle to increase signal to noise ratio on the spectral, the samples were then filled into a rotor and 
spectra taken after prior calibration to a pw90H value of 2.5µs.
2.3.7  Raman spectroscopy/microscopy
Raman spectra were collected using a confocal Horiba-Jobin-Yvon LabRAM system, using a 600 
lines/mm grating and a 785 nm excitation laser. A Synapse CCD detector was employed. 
Temperature control was achieved using a Linkam hot-stage (Linkam Scientific Instrument Ltd, 
Surrey U.K). Samples were heated at stepwise 1°C min-1 intervals, and were held at temperature 
during data collection (typically 10–20 s maximum). Data sets were collected every 1°C. Samples 
(approximately 1 mg) were contained between a glass microscope slide and cover slip.
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2.4   Results and Discussion
2.4.1  X-Ray Powder Diffraction 
As previously mentioned, the XRPD pattern of the as received sample of FFA showed that it is 
Form I121, while the samples obtained from slow evaporation (propanol, xylene and toluene only) 
and solvent drop techniques (except using water) was found to be Form III122 of FFA  after 
calculations using mercury and comparison with single X-ray diffraction patterns downloaded from 
the Cambridge Structural Database (CSD), as previously obtained in literature. The XRPD patterns 
are shown in figure 2.2:
                                               Figure 2.2: XRPD patterns of FFA
 A = XRPD pattern for as received, B = Simulated FFA I, C = XRPD pattern of FFA I dry milled 
with FFA III,  D = Simulated FFA III, E = Representative XRPD pattern for samples obtained from 
solvent evaporation and solvent drop milling experiments
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Figure 2.3 shows a series of XRPD traces collected from samples of FFA I milled for different 
amounts of time, extra peaks are seen to appear after 30 minutes of milling (see left hand side of 
2.3). After 40 minutes the two forms (I and III) co-exists. And after an hour of milling the pure form 
I is obtained after comparison with previously published data.58  Worth noting from figure 2.3 below 
is the XRPD trace obtained after 50 minutes of milling which shows a pattern for pure FFA form 
III, this we believe is due to experimental set up (for the longer milling times i.e. 50-60mins, it 
becomes more difficult to remove the milled samples from the jar because the samples stick to the 
side of the jar, a spatula is used to scrape the samples out, this we believe could affect the molecular 
orientation of the samples). FFA form I does not transform into any other form upon dry milling 
irrespective of time of milling.
Figure 2.3 below shows the various patterns obtained as the milling experiment progressed:
                      Figure 2.3: Patterns obtained from the dry milling experiment with FFA III
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Figures 2.4a and 2.4b shows both the phonon-mode and molecular-mode Raman spectra of both 
forms of FFA, the phonon region can be easily used to distinguish between forms I and III and thus 
will be used to monitor how milling affects the system. The molecular-mode spectra are similar, 
expected as both samples contain FFA molecules.
Figure 2.4a Raman spectra of the phonon-mode          Figure 2.4b Raman spectra of the molecular- 
of both forms I and III             mode of both forms I and III
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Figure 2.5 shows the transformation of FFA form III to I (induced by dry milling) monitored using 
Raman spectroscopy, thereby complementing the earlier results obtained with XRPD:
              Figure 2.5: Raman spectra showing FFA III→I transformation upon dry milling
Using the phonon-mode region only, both forms I and III are easily differentiated ( form I has four 
prominent peaks while form III has two), as the milling progresses in figure 2.5 above, after 20 
minutes of milling both forms co-exists, typified by the appearance of additional peaks. These peaks 
continue to increase in intensity until the transformation is completed after 60 minutes of milling.
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Similarly, figure 2.6 below shows the solid-solid transformation of FFA III → I (heating) monitored 
using variable temperature XRPD:
        Figure 2.6: XRPD patterns of the solid-solid transformation between FFA forms I and III
As shown above the solid-solid FFA form III to I transition takes place between 110-120°C rather 
than at 42°C when the transformation is solvent mediated.
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XRPD traces for the product of co-milling form I with a variety of solvents are given in figure 2.7a. 
From visual inspection of the data it is immediately apparent that form I transforms into form III in 
all cases expect when milled with water.
While form III remains unchanged irrespective of the solvent used as shown in figure 2.7b.
                           Figure 2.7a:  XRPD patterns of FFA I after solvent drop milling
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                            Figure 2.7b: XRPD patterns of FFA III after solvent drop milling
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The above results as shown in figures 2.6, 2.7a and 2.7b respectively, clearly show that XRPD is a 
very effective method for distinguishing between the two forms. Also, at first glance the theory that 
transformations during milling are due to heat build-up seems to tie in with the results, but the effect 
of solvent is clearly important as well. So it is not a surprise that no transformation was observed 
when both forms of FFA were milled with water as they are both insoluble in water, whereas when 
form I is milled with all the other solvents used in the study, a transition is obtained as both forms 
are soluble in all the solvent used. Thus a dissolution/recrystallisation mechanism seems appropriate 
for the solvent-drop milling.
 
32
2.4.2  Solubility assays
Table 3 below shows the results of the basic solubility assay carried out on the as received sample.
Table 3: Solubility table for flufenamic acid as received
Solvent Soluble
Acetone Yes
Chloroform Yes
Methanol Yes
Methylated Spirit Yes
Propanol Yes
Toluene Yes
Xylene Yes
Water No
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2.4.3  Solvent milling experiment
From the solvent milling experiments, the table below was arrived at to depict the polymorphic 
transformations.
Table 4: Result of solvent drop milling experiments of FFA forms I and III
Form before solvent milling Solvent used in milling Form obtained after solvent 
milling
FFA I Methanol FFA III
FFA I Acetone FFA III
FFA I Ethanol FFA III
FFA I Propanol FFA III
FFA I Toluene FFA III
FFA I Chloroform FFA III
FFA I Methanol and Water FFA III
FFA I Methylated Spirit FFA III
FFA I Water FFA I
FFA I None FFA I
FFA III None FFA III
FFA III Methanol FFA III
FFA III Acetone FFA III
FFA III Ethanol FFA III
FFA III Propanol FFA III
FFA III Toluene FFA III
FFA III Chloroform FFA III
FFA III Methanol and Water FFA III
FFA III Methylated Spirit FFA III
FFA III Water FFA III
 
PS: Neat grinding (solvent free) of both forms I and III together yielded equimolar (approximately) 
amounts of both forms, this was confirmed by XRPD.
34
2.4.4  Molecular modelling
In order to see if a simple theoreticalmechanism can explain the interconversion between the 
conformations I and III of FFA, molecular modelling was deployed (Monte Carlo simulation).123,124 
It must be noted however that this technique has some limitations: Solid phase packing and inter-
molecular hydrogen bonding are not allowed for.
                    Figure 2.8a: Molecular 
        structure of FFA
                    Grey atoms = Carbon
                    Blue atoms = Nitrogen
                    Red atoms = Oxygen
                    Green atoms = Fluorine
Figure 2.8b: Energy of gas-phase 
FFA molecule as a function of the 
two nitrogen-centred torsion angles
                            
                                         
The molecular structure and the calculated gas-phase energies of the FFA molecule are presented in 
figure 2.8a and 2.8b respectively and compared with the molecular conformations in the 
polymorphs I and III. The molecule exhibits nearly free rotation about the N:m-
trifluoromethylbenzene bond (direction indicated by arrow a). Rotation about the N:o-benzoic acid 
bond is sterically hindered (direction indicated by arrow b). In neither polymorph do the molecules 
adopt a gas-phase energy minimum conformation. From these calculations (which assume an 
isolated molecule in the gas phase), the molecular conformation of form III is of lower enthalpy 
than that of form I. 
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It should be noted that in the solid state effects like lattice energy and non-bonded interactions are 
likely to have a very significant effect on the relative energies of the two forms.
2.4.5  Solid-state NMR
In order to further distinguish between the two forms of  FFA, solid-state NMR was employed, and 
despite the obvious advantages of this technique (e.g. over other methods such as XRPD and 
Raman) which include: its non-invasiveness, minimal sample requirement/preparation, it is also 
highly quantitative and selective, it also has its own draw-backs: it is very expensive, it often 
requires a lot of expertise in the technique to run it properly, automation is difficult and 
experimental parameters need to be pre-determined for every experiment.   
Although the assignment of the various peak positions are non-trivial, the NMR spectral in figure 
2.9 below also showed that the two forms are different.
                                     Figure 2.9: Solid-state NMR spectral of FFA I and III   
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2.4.6  Differential Scanning Calorimetry (DSC)
Representative DSC data for FFA forms I and III (10°C heating rate) are presented in figure 2.10 
below:
                                          Figure 2.10: DSC plots for both FFA forms I and III
The two DSC traces appear broadly similar: both exhibit a large endothermic event with an onset 
temperature of 132.2°C and an enthalpy of 95.8kJ/mol (data for both I and III being the same within 
experimental uncertainty). The temperature of this event corresponds well with the reported melting 
temperature of FFA.80 However, on closer inspection of the two traces (inset, figure 2.10) a clear 
difference becomes apparent: form III, but not form I, exhibits a weak endothermic transition with 
an onset temperature of 104°C and an enthalpy of 4.3 kJ/mol. This value corresponds to the enthalpy 
difference between forms I and III, and the endothermic nature of the transformation indicates that 
the driving force for the transformation is an increase in entropy on moving from form III to form I.
These data therefore suggest that under these experimental conditions form I remains stable until 
132.2°C, at which it melts, whereas form III transforms into form I at 104°C, with the newly 
crystallized form I melting at 132.2°C. 
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From figure 2.10 the III to I transition is endothermic, and application of the rules for polymorph 
stability outlined by Burger and Ramberger20 suggests that the relationship between forms I and III 
is enantiotropic, i.e. the free energy versus temperature curves of the two solid forms cross, and the 
transformation is reversible.
       
A number of experiments were performed in order to probe the enantiotropic nature of this 
transition, including heating a sample of form III until it melt, cooling the melt down to -20°C and 
reheating again, this was done four times using the initial starting sample, it was observed that only 
on the first heating was the event at 104°C evident. We therefore conclude that either: (a) the FFA III 
to I transition is in fact monotropic and that the Burger and Ramberger rules are not applicable in 
this case; or (b) the reverse transformation is kinetically hindered. 
We are unable to determine which of these is the case, as it seems reasonable to suppose that a 
solid-state transition between two conformational polymorphs such as FFA I and III would be 
highly sterically hindered and therefore kinetically hindered as well as earlier depicted from the 
molecular modelling results.
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2.4.7  In situ Raman spectroscopy/microscopy
The data in figure 2.11a and 2.11b shows the phonon-mode and molecular-mode Raman spectra of 
both FFA forms I and III
                            Figure 2.11a: Phonon-mode Raman spectra of FFA forms I and III
  
                      Figure 2.11b: Molecular-mode Raman spectra of FFA forms I and III
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At room temperature the two polymorphs, forms I and III, exhibit markedly different Raman 
spectral (figure 2.11a and 2.11b).
The two spectra from the two solids forms of FFA are readily distinguished by eye, with peaks at 
1003.8(995.1), 1046.9 (1045.6), 1253.1 (1249.3), 1596.4 (1586.7), 1617.3 (1615.1) cm-1 for form I 
(and III) respectively, etc. As forms I and III are conformational polymorphs, the different 
molecular arrangements in the crystal structures lead directly to these strong differences in 
molecular vibrational bands (400-4000cm-1).
The Raman spectra (2.11a) show the low wave number bands (40-400cm-1) due to lattice vibrational 
modes (this region provides useful information about lattice environment), this is the first time that 
these data have been presented for this system, and one of a very limited number of phonon-mode 
data sets collected to date on pharmaceutical systems (emphasis in previous publications51, 53-70 were 
placed on the  fingerprint region 500-2000cm-1, where intra-molecular vibrations dominates), 
absorptions in the low wave number region are also more intense than the bands due to intra-
molecular vibrations which makes it useful in distinguishing between crystalline as well as 
amorphous materials. 
While 2.11b, the high wave number bands can be used to deduce information about the molecular 
vibrations in the molecule : as expected for two polymorphs (necessarily having different crystal 
structures), the lattice modes are extremely different for the two forms. The same differentiation in 
peak widths is observed for the molecular stretches, for example the phenyl symmetric breathing 
mode at 1003.8(995.1) cm-1 has a width of 2.98(4.33) cm-1 in form I (and III). The bands for form I 
appear sharper and therefore better-resolved than those of form III. 
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In order to investigate the transformation between form I and III suggested from the DSC 
experiments (to further investigate the nature of the solid-solid transition i.e. whether it is abrupt or 
not), in-situ experiments were performed in which the samples were heated at 1°C/min from -45°C 
to 145°C, with a Raman spectrum being collected every 1°C for the representative spectral window 
40-2000 cm-1. A total of 153 spectra were collected for each of the two samples.
Pertinent data from these experiments are presented in figure 2.12a and 2.12b (intensities in colour):
           Figure 2.12a: Variable temperature Raman Spectroscopy experiment of  FFA form I
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          Figure 2.12b: Variable temperature Raman Spectroscopy experiment of  FFA form III
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On heating form I (figure 2.12a), no changes are apparent until 135-145°C, at which point a major 
change in spectra occurs. Many of the peaks decrease in intensity and increase in width, including 
the lattice vibrations (40-400cm-1). Optical inspection of the sample before and after this transition 
confirms that this corresponds to the sample melting.
The melting point is slightly higher, and broader, than that from the DSC experiments, and this is 
almost certainly a result of the different sample configurations employed in the two methods. The 
DSC data were recorded in a small aluminium pan heating at 1°C/min, where as the Raman data 
were collected on a sample contained in a microscope hot-stage, supported on a glass microscope 
slide and under a cover slip.  
The heat transfer is expected to be more efficient in the DSC than in the microscope hot-stage, and 
this explains both the greater width and the slightly higher temperature of the transformation in the 
Raman experiments.
In contrast to the simple behaviour exhibited by form I, the spectra for form III change abruptly 
between 114 and 115°C (figure 2.12b). Visual inspection of the spectra, and comparison with room 
temperature data from the two polymorphs, indicates that below this temperature (114-115°C) form 
III is present, and above that form I. No region of co-existence of the two phases is apparent (as 
depicted in figure 2.13 below).                       
                     
Figure 2.13: Representative Raman spectra from the heating FFA form III taken between 113-    
         116°C
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The change in peak position and peak width (using a Gaussian fit) of the symmetric phenyl 
breathing mode around 1000cm-1 (this peak was chosen because of its high intensity and the unique 
molecular structure of FFA ; made up of two phenyl rings) on heating across the transition is 
reported in figure 2.14 below:
                Figure 2.14:  Plot of peak width and peak position as a function of temperature
On approaching the transition from below, the peak position exhibits a gradual increase from ca. 
995 cm-1 at 100°C, to 996.5 at 113°C. It then jumps to 997.1 at 114°C, 998.0 at 115°C, and then 
levels off to 998.3-998.5cm-1 until the melting point.
The higher peak position for form I (above the transition temperature) is in full agreement with the 
data from room temperature. The variation in peak width is also presented in figure 2.14.
The peak width below the transition is greater than that above the transition, which again is in full 
agreement with the room temperature data on forms I and III. Despite the decrease in peak width on 
transforming from form III to I, as the transition is approached the peak width increases from ca. 
4.5cm-1 to ca. 5.3cm-1, before decreasing to ca. 4.1cm-1 after the transition.
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Note again that no region of co-existence of forms I and III is apparent in Raman, and that this peak 
broadening therefore has its origin purely in the molecular motion in form III. 
The increase in peak width over several degrees Celsius as the transition is approached indicates 
that (averaged over the experimental time scale of ca. 4 seconds) the FFA molecules in form III can 
adopt a wider range of vibrational energies (and hence local molecular environments for the phenyl 
ring) as the transition is approached. This observation further shows the unique advantage of Raman 
spectroscopy over the other techniques used in polymorphic identification/characterisation as it 
allows us to explore molecular changes as a function of temperature.
A possible mechanism for the transformation can be envisaged, using vibration of atoms in the 
crystal to explain the melting transition, this resembles the so-called Lindemann vibrational 
catastrophe (in its simplest form suggests that melting is a spontaneous process i.e. the solid and the 
liquid phase does not co-exists at any time during the melting process) in melting theory.125-134 In 
this mechanism, melting is assumed to occur when the amplitude of vibration of the atoms reaches a 
certain fraction of the equilibrium atomic spacing, Lindemann's model assumes that the vibrations 
of the atoms are harmonic, with a common frequency. Quantitative calculations based on the model
are not easy, hence Lindemann offered a simple criterion: melting might be expected when the root 
mean vibration amplitude √˂u2> exceeds a certain threshold value (namely when the amplitude 
reaches at least 10% of the nearest neighbour distance). 
The average amplitude of thermal vibrations increases when the temperature of the solid increases, 
at some point the amplitude of vibration becomes so large that the atoms start to invade the space of 
their nearest neighbours and disturb them and the melting process initiates. The sudden surge in 
peak width (suggesting rather rapid increase in disorder) is a further pointer towards the assumption 
of the Lindemann model.
Conclusions
It is clear from the above study that FFA I and III are both conformational polymorphs.
Above the thermodynamic III ->I transition temperature we see III -> I (using Raman hot-stage), 
whereas below it (as seen from the room temperature solvent drop milling and slow evaporation 
results) we tend to see I -> III. i.e. we tend to see the thermodynamically most stable form at 
ambient temperature.
FFA III transforms to FFA I on heating, the transition is vibrationally driven, with both forms easily 
distinguishable by Raman spectroscopy, with the low wave number region or phonon-mode region 
being highly valuable for studying polymorphs.
While the transition is abrupt with no co-existence of the two forms in the Raman analysis, this is 
not so with XRPD where the transformation proceeds via a mixture of the two forms, this is because 
the Raman experiment involved only a microscopically small amount of sample (as it uses a 
microscope) whereas the XRPD looks at significantly more sample.
The mechanism of the transition is similar to the 'Lindemann melting theory' as indicated by the 
rapid increase in disorder during the transformation.
The large number of polymorphs of FFA is thought to arise from a delicate balance between 
molecular conformation, hydrogen bonding and crystal packing.
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3.0  Polymorphic Transformations in Flufenamic Acid
3.1   Monitoring polymorphic changes in flufenamic acid using variable  
temperature X-ray powder diffraction and in situ Raman 
spectroscopy  
While in the last chapter (2), the study focussed on the transitions between two crystalline forms of 
FFA (i.e. I and III), this chapter (3) looks at the amorphous form and what happens when we heat it.
A previous study has shown that the amorphous can be an intermediate in some crystals prior to 
crystal transformations.6 The main purpose of this study is to show that the method of constrained 
crystallisation (slow heating of the amorphous state/form) can be a veritable tool for studying 
polymorphism.
Abstract
The aim of this study was to use variable temperature X-Ray Powder Diffraction (VTXRPD) and in 
situ Raman spectroscopy to monitor the polymorphic transformations in flufenamic acid (FFA) 
forms I and III using the constrained crystallisation approach. 
Initial results from the VTXRPD experiments using FFA form I showed a transformation to a new 
form at 50°C, this then transforms into form II (70°C) and then back to form III at 90°C before 
melting at 140°C. While heating form III produced only a transition back to form I.
In situ data from the Raman experiments revealed that FFA form I, changed first to form III and 
then back to its original form (I) before melting, while the same transformation as obtained with the 
VTXRPD experiment on form III (form III →form I) was observed also with the Raman 
experiment.
Differential Scanning Calorimetry (DSC) was also used similarly to support the findings observed 
above from the VTXRPD and Raman experiments. Principal component analysis was used in 
analysing the data obtained from the in situ Raman experiments.
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3.2   Experimental
3.2.1   Materials
Flufenamic acid form I (confirmed using DSC, XRPD and Raman spectroscopic analysis and 
results compared with already published data40,41), was purchased from Sigma-Aldrich Dorset UK 
was used in all experiment as received.
Pure flufenamic acid form III was prepared by simple evaporative crystallisation (of FFA I) from 
propanol and its spectroscopic data confirmed like in the case of form I.
3.2.2   DSC 
A Q2000 series differential scanning calorimeter, manufactured by TA Instrument, Crawley, 
England, was used for the DSC analysis. Approximately 4mg of both forms were first heated at 
1°C/minute to 150°C, cooled down to -100°C at 1°C/minute before subsequently heating the 
supercooled sample slowly at a heating rate of 1°C/minute back to 150°C.
3.2.3   XRPD
XRPD patterns were collected on a Bruker D8 diffractometer system (Bruker AXS, Madison, WI, 
USA), operating in a Debye-Scherrer geometry, at a wavelength (λ) of 1.54059Å, 40kV voltage, 
and a current of 40mA, using a LynxEye detector. The sample was heated using a Cryostream plus 
controller (Oxford Cryostreams Ltd. Hanborough Oxford OX29 8LN) at 3OC/minute from -10°C to 
150°C and patterns were collected at each temperature step (overall accumulation time of 8 minutes) 
at a scan time of 0.3 second.
3.2.4   Raman
Raman spectra were collected using a confocal Horiba-Jobin-Yvon LabRAM system (Horiba-Jobin-
Yvon Ltd Middlesex U.K.), using a 600 lines/mm grating and a 785 nm excitation laser. A Synapse 
CCD detector was employed. Temperature control was achieved using a Linkam hot-stage (Linkam 
Scientific Instrument Ltd, Surrey U.K). 
Flufenamic acid samples were first heated to 150°C, held at this temperature for 2 minutes and 
quenched on a surface that had been pre-cooled to -100OC with liquid nitrogen. 
The super-cooled samples were then heated at stepwise 1°C/ minute intervals, and were held at 
temperature during data collection (typically 10–20 seconds maximum). Data sets were collected 
every 1°C. Samples approximately 1 mg were placed on a microscope slide without a cover slip.
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3.2.5   Data Analysis
The Raman spectra obtained were subjected to PCA analysis using 'PCA packages' within the 'R' 
programming suite. Raw spectra were used, the phonon spectra range/mode (30-400cm-1) and 
molecular fingerprint range/mode region (500-2000cm-1) were used for the analysis.
The most important principal components (PCs) were determined from percentage variance plots 
and were used to investigate trends in the spectra features of the Raman data. PC1, PC2 and PC3 
were selected as they accounted for over 90% of the variance.
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3.3   Results and Discussion
3.3.1   X-ray powder diffraction
The powder patterns obtained from the heating of amorphous samples prepared from FFA form I 
are shown in figure 3.1 below:
   Figure 3.1: In situ XRPD pattern from the heating of the amorphous form prepared from FFA I
The pattern (figure 3.1) shows a transformation to a new form135 at 50°C, which transforms into 
form II (70°C) and then to form III at 90°C before melting at 140°C. The XRPD pattern of Form II 
has not yet been published (its structure was determined from single crystal X-ray at a synchrotron).
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3.3.2   Confocal Raman spectroscopy
The in situ Raman spectra of the slow heating of the amorphous samples obtained from FFA forms I 
and III are presented in figure 3.2a (left hand side) and 3.2b (right hand side, intensities in both 
cases are in colours, PC1 is black and PC2 is red): the amorphous form obtained from either forms 
are expected to be the same, therefore forms I and III refer only to the crystalline forms.
Figure 3.2a: Variations in the Raman spectra                 Figure 3.2b: Variations in the Raman spectra 
(top right), PC1, PC2 (top left) with                     (top right), PC1, PC2 (top left) with  
temperature and loadings (bottom), for the                    temperature and loadings (bottom), for the
slow heating of the amorphous form obtained               slow heating of the amorphous form 
from FFA I                                                                       obtained from FFA III
         
                               
Visual inspection of figure 3.2a shows two separate events occurring as the amorphous sample 
(prepared by melting FFA I) is being heated: at 50°C and 100°C respectively (see left hand side 
panel i.e. scores). While the lower panel (loadings) only shows significant changes in the phonon-
mode region as the sample is being heated.
While in figure 3.2b, four separate events are observed (see left hand side panel): at ~ 34°C, 59°C, 
80°C and at 100°C respectively during the heating of the amorphous sample (obtained by melting 
and quenching FFA III) . Similarly the phonon-mode region as seen in the lower panel of figure 
3.2b undergoes noticeable changes in the course of the experiment.
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Further data treatment using principal component analysis (PCA), enumerates the transition 
observed from the in situ Raman experiments. Figures 3.3a and 3.3b, shows the principal 
component projections for the phonon-mode as well as molecular-mode region for the slow heating 
of amorphous form obtained from melting FFA I:
Figure 3.3a: Phonon-mode projection of the heating of amorphous form (prepared by melting 
                    FFA I)                                       
Figure 3.3b: Molecular-mode projection of the heating of amorphous form (prepared by melting  
        FFA I
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While figures 3.4a and 3.4b show a similar principal component projection for the in situ 
experiment involving the amorphous form (obtained by melting FFA III), here the phonon-mode 
projection better describes the transition than the molecular-mode. These plots i.e. 3.2a, 3.2b, 3.3a, 
3.3b, 3.4a and 3.5b shows that the PCA highlights transformation, scores allows temperature of 
transitions to be picked, while loadings tells us about peak changes.
                    
   
Figure 3.4a: Phonon-mode projection of the heating of amorphous form (obtained by melting 
        FFA III)                                  
Figure 3.4b: Molecular-mode  projection of the heating of amorphous form (obtained by melting  
        FFA III)                 
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3.3.3   DSC Analysis 
Figure 3.5a below shows the DSC trace obtained from the slow heating of the amorphous sample 
prepared by melting and quenching FFA I (1°C heating rate): further analysis revealed  an exotherm 
at ~ 39°C, followed by two weak endotherms at approximately 126.4°C and 128°C (inset, figure 
3.5a) respectively, before the final melting of the sample at 133.4°C.
          Figure 3.5a: DSC trace of the slow heating of amorphous sample prepared by melting and 
                  quenching FFA I: inset are the two weak exotherms
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The representative DSC trace from the heating of the amorphous sample prepared by melting and 
quenching FFA III is shown in figure 3.5b below: two exotherms at 38.7°C and 54.7°C were 
observed before the final melting at 133.4°C.
         Figure 3.5b: DSC trace of the slow heating of amorphous sample prepared by melting and 
                  quenching FFA III
Figure 3.5a shows a glass transition (at ~ 39°C), followed by two successive melting events before 
the final melting event (at 133.4°C) suggesting that two separate forms of FFA could be obtained 
from the slow heating of its amorphous form (prepared from FFA I). While figure 3.5b; shows two 
separate recrystallisation events, an indication that has the heating progresses two different 
polymorphic transformation occurs. 
This rich display of polymorphism by FFA as seen in the DSC traces (figures 3.5a and 3.5b) is in 
agreement with previous publication by J. Krc Jr.,80 who suggested that FFA could adopt several 
polymorphic transitions as a result of an interplay of both its molecular conformation, hydrogen 
bonding sequence and its unique crystal packing.
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Conclusions
In concluding, the use of the constrained crystallisation approach in inducing polymorphic 
transformation is a veritable tool for monitoring polymorphism as shown in this study: especially 
when monitored using a combination of in situ Raman spectroscopy and variable temperature 
XRPD. The results obtained in the study compares favourably well with those obtained using other 
techniques traditionally used to induce polymorphic transitions. Two new powder x-ray patterns of 
FFA  were also uncovered in the study. The use of PCA in analysing the data obtained from the 
study was very helpful, allowing for easy visualisation of not only the transformations but also the 
temperature at which these transformations occurs as well as changes in peak positions as the 
experiment progressed. The differences in the transformation temperature observed in the DSC 
experiment as compared to the Raman analysis we adduce to the slightly different experimental set 
up in the two techniques: In DSC the samples are heated inside aluminium (covered) pans while 
they are heated on a microscope slide during the Raman experiment. 
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4.0   Polymorphism in Nifedipine
4.1   In situ investigation of the polymorphic transformations from 
amorphous nifedipine using Raman spectroscopy
Abstract
We report a novel investigation into the polymorphic transformations of nifedipine (a calcium-
channel blocker) from its amorphous form using in situ variable temperature Raman (confocal) 
spectroscopy, by employing the constrained crystallisation approach (heating of the amorphous 
form). Our results were complemented with Differential Scanning Calorimetry (DSC) and variable 
temperature X-Ray Powder Diffraction (XRPD). 
Initial visual analysis of the Raman spectroscopic data from the slow heating experiments showed 
that amorphous nifedipine transforms into form II at approximately 52°C and back to the as received 
form I at 75°C before finally melting at 175°C. While heating the amorphous sample first to 180°C 
and cooling to room temperature, before slowly reheating back to the melting point gives form II at 
room temperature, form III at ~28°C and form I at 75°C. Forms II and III are endothermically 
related ( by applying the Burger and Ramberger rule) as previously reported.136 
DSC analysis of the melt and quenched sample of the as received (form I) showed a glass transition 
(Tg) at ~ 43.3°C, followed by two exotherms (98.7°C and 112.6°C) and an endothermic event 
(melting) at 170.5°C.
While patterns obtained from the in situ XRPD analysis of the melt and quenched sample of 
nifedipine form I, identified that amorphous nifedipine transformed to form II and then back to form 
I. 
The diffraction patterns obtained from the reheat of form II (prepared by cooling the melt and 
quenched sample of form I to room temperature), showed the presence of two intermediates which 
appears to be a mixture of both forms I and II before transformation back to form I .
 A multivariate approach was adopted for a more detailed analysis of the Raman data by using 
Principal Component Analysis (PCA). 
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4.2   Introduction
Nifedipine (dimethyl-1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)pyridine 3,5-dicarboxylate), 
shown below is known to exhibit polymorphism, a fact that has been well documented in 
literature.136-147
                                       
  
                                           Figure 4.1: Molecular structure of nifedipine
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Using DSC and thermomicroscopy, Eckert and Muller137, concluded that two modifications i.e. form 
II (fine ray-shaped aggregates) with melting point between 162°C and 164°C and form III (beam 
shaped) with melting range 134°C to 137°C can be obtained from the supercooled melts of 
nifedipine (most thermodynamic stable form I), with melting point between 172-172.5°C.
While Burger A. and K.T. Koller138 monitored the crystallisation of the supercooled melt of 
nifedipine using Infra-Red (IR) spectroscopy, findings were similar to that of Eckert et al. They 
summarised their results by claiming: nifedipine exists in three monotropically related 
modifications. Form I (melting point. 169 to 173°C) is the thermodynamically stable modification at 
room temperature. The two unstable modifications form II (melting point. 161°C to 163°C) and form 
III (melting point. 135°C) could only be obtained from the melt on a object slide.
They were the first to present the IR spectra of nifedipine forms II and III, they also prepared four 
different solvates (A,B,C and D) of nifedipine by crystallisation from 1,4-dioxane.
Hirayama139 et al. studied the crystallisation of amorphous nifedipine with and without  a 
cyclodextrin derivative added, and confirmed that supercooled nifedipine in the absence of the 
derivative crystallises first to a metastable  form II around 110°C , which then reconverts to the 
thermodynamically stable form I at 125°C using (XRPD). The presence of the derivative was 
reported to slow down the rate of crystallisation of amorphous nifedipine to form I and a form II 
melt was obtained at 163°C.
The results published by Aso140 et al. showed that the supercooled melt of nifedipine crystallised 
from the amorphous state to a metastable form II at 90°C which then enantiotropically reconverted 
to the thermodynamic stable form I around 110°C.
Bram Keymolen143 et al. reported that recrystallisation, solid-solid and solid-liquid-solid 
transformations processes occurred in glassy nifedipine when heated from 45°C to its final melting 
point of 172°C, including a glass transition ~48°C. They concluded that there are probably four 
polymorphic forms of nifedipine. 
D. Grooff144 et al. monitored the thermal behaviour of nifedipine with the view to understand the 
various phase transitions between its polymorphs using a combination of DSC, MTDSC, TG, HSM, 
PXRD and VTPXRD. They concluded from their results that the metastable form II, melting point 
~163°C, was enantiotropically related to a third modification, form III, which existed at a lower 
temperature. Form III converted endothermically to form II at ~56°C on heating and was shown by 
HSM to be accompanied by morphological changes. Discontinuities in the reversing heat flow 
signal during crystallisation of amorphous Nifedipine ( from ~92°C) to form II, suggested that a 
number of polymorphs may nucleate from the melt prior to form II formation.  
Chan145 et al. reported on polymorphism in nifedipine under controlled humidity, their results 
showed that glassy nifedipine crystallises to the thermodynamically stable α-polymorph (form I) via 
a transient metastable β-nifedipine (form II) phase. Increasing relative humidity in the range 20-
60% is found to favour the surface crystallisation of the glass β-nifedipine while at high relative 
humidity (80%), β-nifedipine is rapidly converted to α-nifedipine.
D. Zhou136 et al. reported their study on the crystallisation of amorphous nifedipine using hot-stage 
microscopy (HSM), (PXRD), and (DSC). The kinetic data obtained from DSC studies under 
isothermal and non-isothermal conditions were examined using both model-fitting and model-free 
approaches. 
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Their results concluded that amorphous nifedipine transforms into form II upon heating at around 
105°C, which then undergoes a solid-solid transformation back to form I at ~145°C, they also found 
out that by cooling the sample of form II back to room temperature, a small exotherm appeared at 
30°C during cooling and a small endotherm appeared at 60°C during subsequent heating, they then 
concluded that this shows the presence of a polymorphic transformation between form II and 
another form. The reverse event occurs during the cooling process, thus indicating that forms II and 
this third form are related enantiotropically.
Caira148 et. al. reported for the first time the single-crystal structure of the solvated species 
(nifedipine)2. 1,4-dioxane. They also showed that desolvation of these species involves complete 
disruption of the crystal structure at the relatively high temperature of 150°C-153°C, i.e., 50°C above 
the boiling point of 1,4-dioxane, and yields a monoclinic polymorph (modification I) with a melting 
point of 174°C. When exposed to an aqueous medium for 48 hours, the solvate transforms into a 
dihydrate.    
It is also worth mentioning that the crystal structure of nifedipine (modification I) was first reported 
by  Triggle et al.148
Table 5 Below summarises the results obtained by the various authors previously mentioned.
Authors and year of publication Analytical methods/techniques 
used
Form(s) of nifedipine 
obtained/isolated
 T. Eckert and J. Muller 
(1976)137
DSC and thermomicroscopy Forms II and III (from form I)
A.M. Triggle et. al. (1980)163 XRPD Crystal structure of form I
Hirayama et. al. (1994)139 XRPD Forms II and III (from form I)
Aso et. al. (1995 & 2001)140 Microcalorimetry Form (II from form I)
Keymolen et. al. (2003)143 Thermomicroscopy Suggested the possibility of 
four different forms
Zhou et. al. (2003)136 HSM, XRPD and DSC Form II and a 'possible' third 
form (from form I)
Caira et. al. (2003)147 Single-crystal XRD Nifedipine dihydrate
Chan et. al. (2004)146 FT-IR, FT-Raman and Raman 
microscopy
Forms I and II (from form I)
Burger et. al. (2006)138 IR Forms II and III (from form I), 
solvates A, B, C, & D
Grooff et. al. (2007)144 DSC, MTDSC, TG, HSM, 
PXRD and VTPXRD
Forms II and III (from form I), 
and suggests the possibility of 
the existence of some other 
forms
       Table 5: Summary of previous publications on the polymorphic modification of nifedipine
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The crystal structure of nifedipine first reported by A.M. Triggle et. al. (1980),148 was found to be 
similar to that described by Caira et al.147 crystallizing in the space group P21/c with Z¼=4; the 
structural arrangement clearly favouring the emergence of likely hydrogen bonding between 
molecules of nifedipine leading to different structural possibilities.
Polymorphic transformations can be studied in situ by infra-red and Raman micro-spectroscopy 
combined with a controlled environment unit.143,149,150 Compared to DSC and XRPD, Raman 
spectroscopy does not require sample isolation and invasive preparation before data acquisition.162
This study will focus on monitoring the polymorphic modifications from the melt quenched sample 
of the commercially available form (form I) of nifedipine, this will involve applying chemometric 
methods and in-situ Raman, including phonon-mode data, to a controversial system (Bram 
Keymolen et.al. found out that the order of transitions (using DSC) from the amorphous form was 
not as previously reported by143 by Hirayama et. al.,139  this they postulated could be dependent on 
heating rates). We will also compare the results obtained from the Raman analysis with data from 
similar experiments using DSC and in situ XRPD.
We will adopt the nomenclature used by Eckert and Muller,137 in identifying the various form of 
nifedipine in this study. Because of the usefulness of PCA in data classification,151-153 it was 
employed in this study to explain trends in the data acquired from the in situ experiment (Raman 
spectroscopy).
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4.3   Experimental
4.3.1   Material 
Nifedipine, was purchased from Sigma-Aldrich CO, 3050 Spruce Street, St. Louis, MO 63103 USA 
and used in all experiment as received. The as received sample was identified as nifedipine form I 
by DSC and XRPD analyses after comparison with previous results published by Zhou et. al.136 and 
Groof et.al.144
4.3.2   DSC
A Q2000 series differential scanning calorimeter, manufactured by TA Instrument, Crawley, 
England, was used for the DSC analysis. Approximately 4mg of the as received sample was 
accurately weighed and was first heated at 1°C/minute to 180°C, above the melting point, cooled 
down rapidly to -40°C at 40°C/minute before subsequently heating the supercooled sample slowly at 
a heating rate of 1°C/minute back to 180°C. For the reheat of nifedipine form II (obtained by cooling 
a melt quenched sample of form I to room temperature), 2.77mg of the as received sample was 
weighed, heated at 10°C/minute to 180°C, and subsequently quenched at 40°C/minute to room 
temperature (20°C), before a slow reheat was performed at 1°C/minute to 180°C.
4.3.3   Raman spectroscopy
Raman spectra were collected using a confocal Horiba-Jobin-Yvon LabRAM system (Horiba-Jobin-
Yvon Ltd Middlesex U.K.), using a 600 lines/mm grating and a 785 nm excitation laser. A Synapse 
CCD detector was employed. Temperature control was achieved using a Linkam hot-stage (Linkam 
Scientific Instrument Ltd, Surrey U.K). 
Nifedipine samples were first heated to 180°C above the melting point, held at this temperature for 2 
minutes and quenched on a surface that had been pre-cooled to -100°C with liquid nitrogen. 
The super-cooled samples were then heated at stepwise 1°C/ minute intervals, and were held at 
temperature during data collection (typically 10–20 seconds maximum). Data sets were collected 
every 1°C. Samples (approx. 1 mg together with ~ 0.5mg of ground glass needed to initiate 
nucleation) were contained inside unsealed hermetic DSC pans (T080723) supplied together with 
the Q2000 series differential scanning calorimeter.
4.3.4   XRPD
XRPD patterns were collected on a Bruker D8 diffractometer system (Bruker AXS, Madison, WI, 
USA), operating in a Debye-Scherrer geometry, at a wavelength (λ) of 1.54059Å, 40kV voltage, 
and a current of 40mA, using a LynxEye detector. The sample was heated using a Cryostream plus 
controller (Oxford Cryostreams Ltd. Hanborough Oxford OX29 8LN) at 3°C/minute from -10°C to 
175°C and patterns were collected at each temperature step (overall accumulation time of 8 minutes) 
at a scan time of 0.3 second.
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4.3.5   Data analysis
The Raman spectra obtained were subjected to PCA analysis using 'PCA packages' within the 'R' 
programming suite. Raw spectra (variance-scaled and mean-centred before analysis) were used, the 
entire data range as well as the phonon spectra range/mode (30-400cm-1) and molecular 
fingerprint/mode region (500-2000cm-1) were used for the analysis.
The most important principal components (PCs) were determined from percentage variance plots 
and were used to investigate trends in the spectra features of the Raman data. PC1 and PC2  were 
selected as they accounted for over 99% variance.
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4.4   Results and discussion
4.4.1   DSC
The DSC trace for the slow heating (heating rate 1°C) of the amorphous form of nifedipine (figure 
4.2a below), showed a weak glass transition, Tg (inset) at ~ 43.4°C, a sharp exotherm at 98.7°C (II) 
followed by another exotherm at 112.6°C (I) and an endotherm at 170.5°C (melting).   
   Figure 4.2a: DSC trace of the slow heating of amorphous sample prepared from nifedipine form I
These data is consistent with the following transformations: amorphous → form II (98°C) → form I 
(112°C) → melt (170°C)  and compares favourably well with those reported by Eckert and Muller.137
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Figure 4.2b below shows the DSC plot obtained from the slow heating of nifedipine form II 
(prepared by cooling a melt and quenched sample of nifedipine form I to room temperature, i.e. 
20°C in this case), as described by D.Zhou et. al.150. This was done so as to explore other methods 
of inducing polymorphic transformations in nifedipine for data comparison purposes. 
A gradual exothermic event at 92.88°C was followed by the final melt at 172.50°C (see fig. 4.2b 
below). Thus suggesting one polymorphic transition during the heating of nifedipine form II prior to 
melting.
                                Figure 4.2b: DSC plot of the slow heating of nifedipine form II 
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4.4.2   Confocal Raman spectroscopy
Visual inspection of the in situ Raman spectra from the slow heating of the amorphous form of 
nifedipine (figure 4.3a below, intensities is in colours, PC1 is black, PC2 is red), shows three events 
at 25°C (the Tg), 55°C and 150°C respectively (amorphous → form II → form I) as previously 
reported using thermal methods.138
                      Figure 4.3a: In situ Raman spectra from heating amorphous form of nifedipine
Its worth mentioning here that the above transitions (i.e.  amorphous → form II → form I) were 
obtained only when ground glass was added to the nifedipine sample before quenching to the 
amorphous form and the subsequent slow heating in order to induce nucleation. 
This in essence further shows the robustness of the in situ Raman spectroscopic experimental set up 
used in this study as compared to DSC and VTXRPD where the introduction of the grounded glass 
cannot be achieved without further complications.
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While figure 4.3b below, is the Raman spectra (phonon-mode only) obtained by using the method 
described by Zhou136 et al. i.e.  isolating form II by rapidly cooling the melt quenched sample of 
form I below 30°C (the sample was cooled down to 20°C in this study) before slowing reheating it 
back to the melting temperature. One major transformation were observed at 75°C (suggesting the 
following transition form II → form I).
This result is in agreement with the data obtained from the DSC experiment shown in figure 4.2b.
             Figure 4.3b: In situ Raman spectra of reheating nifedipine form II (phonon-mode only)
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Figure 4.3c below shows the Raman spectra of the molecular-mode region obtained from the same 
experiment (reheat of nifedipine form II).
             Figure 4.3c: In situ Raman spectra of nifedipine (molecular-mode region only)
While the changes are easily discernible by visual inspection in figure 4.3b, it is not so clear in the 
figure above (4.3c). Further showing the advantages of the phonon-mode in monitoring 
polymorphic transformation over the traditional fingerprint region.
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Figures 4.4a and 4.4b below and overleaf shows the changes in the symmetric NO2 stretching mode 
and the ʋ(C=O) vibration as the nifedipine sample is being heated respectively, showing the 
temperature dependent nature of the transformation.
       Figure 4.4a: Raman spectra showing changes in the symmetric NO2 stretching mode
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            Figure 4.4b: Raman spectra showing changes in the ʋ(C=O) vibration stretching mode
These plots (figures 4.4a and 4.4b), seem to suggest that the hydrogen bonding motifs change 
between forms I and II. 
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Figure 4.5a (phonon mode, 30-400cm-1) and figure 4.5b (molecular mode, 500-2000cm-1) shown 
overleaf are the representative Raman spectra for the amorphous and crystalline forms of nifedipine 
obtained from both (heating the super-cooled melt and reheating form II) in situ experiments.
For the first time we report the low wave number (phonon-mode) Raman spectra of the different 
forms of nifedipine, emphasis in previous publications were placed on the fingerprint region 
(molecular mode). Absorptions in the phonon region are are very useful and more intense than the 
bands due to intra-molecular vibrations as they provide useful information about the lattice 
environment and as such this region is very useful in distinguishing between both amorphous and 
crystalline forms of nifedipine as clearly evident in the two figures.
While the different forms are easily distinguishable by visual inspection using the phonon-mode 
spectra (see figure 6a) the difference is not that obvious in the fingerprint region except for the 
peaks around 1600 -1620 cm-1. 
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                                  Figure 4.5a: Phonon mode Raman spectra of nifedipine
                                  Figure 4.5b: Molecular mode Raman spectra of nifedipine
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To further clarify the changes in the Raman spectra as the transition progresses during the heating of 
the amorphous form of nifedipine as well as the reheat of form II, we present a series of principal 
component projections obtained from the analysis of data from the in situ experiments.
Figures 4.6a (below) and 4.6b (overleaf) shows the projections of the entire spectral window (30-
2000cm-1) for the slow heating of the amorphous form (prepared from form I) and the reheat of 
form II respectively:
        Figure 4.6a: Principal component projection of the heating of amorphous form of nifedipine   
From figure 4.6a above, the PCA clearly shows three distinct cluster regions as the heating 
progresses, clearly supporting the observation from the inspection of the in situ experiment that 
amorphous nifedipine goes through an intermediate (form II) before transforming to the stable form 
I. 
This is in agreement with results by other authors137,138,144 and compares positively with the results 
that was obtained with the DSC analysis in this study.
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                 Figure 4.6b: Principal component projection of the reheating of nifedipine form II
Figure 4.6b shows the directionality of the experiment, particularly showing that there is a gradual 
rather than abrupt transformation before form II reverts back to form I. 
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Figures 4.7a (phonon region) and 4.7b (molecular region) below both provides a more precise 
representation of the spectra changes in the Raman data during the transition of the amorphous form 
nifedipine to form I via form II.
       Figure 4.7a: Phonon-mode projection of the heating of amorphous form of nifedipine
      Figure 4.7b: Molecular-mode projection of the heating of amorphous form of nifedipine
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As would be expected figures 4.8a and 4.8b (below) both projections of the reheat of nifedipine 
form II using the phonon-mode and molecular-mode regions respectively also shows a better 
interpretation of the transformations previously depicted in the in situ experiment, with the latter 
showing a smoother trend across the transitions.
                         Figure 4.8a: Phonon-mode projection of the reheat of nifedipine form II
                        Figure 4.8b: Molecular-mode projection of the reheat of nifedipine form II
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4.4.3   Variable temperature XRPD
The pattern obtained from the in situ XRPD analysis is shown below in figure 4.9a, two crystalline 
transformations at 90°C and 140°C were also observed upon heating the amorphous form 
(amorphous → form II → form I). Similar to what was obtained in the Raman experiments and in 
agreement with previously published results by Hirayama.139 The difference in the transformation 
temperature we ascribed to the slightly different experimental conditions employed in the two 
techniques.
    
  Figure 4.9a: In situ XRPD pattern showing the crystallisation of amorphous nifedipine
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The pattern obtained from the slow heating of nifedipine form II using the method described by 
Zhou et al,136 is shown in figure 4.9b below: with two transformations at 55°C and 110°C 
respectively (see left hand side of figure 4.9b).
             Figure 4.9b: In situ XRPD pattern from the reheating of nifedipine form II
Further analysis of the pattern above showed that nifedipine form II undergoes a slow 
transformation with co-existence of two forms as highlighted by the PCA back to form I via two 
similar 'intermediates' (60°C and 66°C, see appendix). These intermediates appear to be a mixture of 
both forms (1 and II), we suggest here that the inability of these intermediates to differentiate into 
distinct crystal patterns might be do to incomplete nucleation, a problem we initially encountered in 
the in situ Raman experiment but was remedied by the addition of ground glass (see experimental 
section). While this is easily achievable in the experimental set up for the Raman, it is not easily 
applicable with variable temperature XRPD experiment without introducing complications.
But it is also worth mentioning that while these intermediates occur with the heating of form II, it 
was not observed in the heating of amorphous nifedipine, thereby suggesting that there could be 
new form(s) present in between forms II and I as previously reported.137,141,144
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Principal component analysis was further deployed to differentiate between the patterns as the 
experiments (in situ XRPD) progresses in both case i.e. heating amorphous nifedipine and the 
subsequent reheat of form II. The results are shown in figures 4.9c and 4.9d below.
   Figure 4.9c: Principal component projection of the heating of amorphous nifedipine (VTXRPD)
  Figure 4.9d: Principal component projection from the reheating of nifedipine form II (VTXRPD)
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Both projections i.e. figures 4.9c and 4.9d, are in agreement with patterns obtained from both 
experiments (VTXRPD).
Conclusion
We have shown that Confocal Raman spectroscopy/microscopy (coupled with hot-stage 
microscopy), can be used as a veritable tool in screening for polymorphism in pharmaceutical 
materials i.e. nifedipine; results obtained from the in situ Raman experiments are in agreement with 
those obtained from other techniques used in this study (DSC and XRPD) and also with those 
previously published in literature.
We have also reported for the first time the phonon-mode Raman spectral of nifedipine; previous 
studies only focused on the traditional fingerprint region. Data analysis is relatively straightforward, 
with visual inspection of the phonon-mode spectra reasonably sufficient to distinguish between both 
amorphous and crystalline forms. 
The Raman analysis also afforded us the unique advantage of being able to monitor various 
structural/molecular changes in nifedipine such as the symmetric NO2 stretching mode, the ʋ(C=O) 
vibration and the hydrogen bonding motifs as the heating progressed.
Sample requirements are of the order of a milligram or less. With further data treatment using 
principal component analysis making it easier to understand and interpret results.
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5.0   Polymorphism in Tolbutamide
5.1   Monitoring polymorphic transformations in tolbutamide using  
constrained crystallisation
Abstract
The polymorphic transitions from amorphous tolbutamide were studied using in situ confocal 
Raman spectroscopy combined with Variable Temperature X-Ray Powder Diffraction (VTXRPD) 
and Differential Scanning Calorimetry (DSC).
Three polymorphic transformations were observed during the slow heating of the amorphous solid 
form of tolbutamide monitored using Raman spectroscopy; amorphous→ form IV → form II→ 
form I respectively.
Similar results were obtained from VTXRPD experiments, with the amorphous solid transforming 
first to form IV (33°C), then to form II (48°C) and back to the as received form I (99°C).
While the DSC data obtained indicated an endothermic event at 83°C, followed by two weaker 
endotherms at 102.3°C and 117.9°C respectively, before the final melting of the sample at ~128.6°C 
(see details and plot in appendix).
Principal Component analysis (PCA), was used to analyse the data obtained from the Raman in situ 
experiment as well as the patterns obtained from the VTXRPD experiment.
5.2   Introduction
Tolbutamide an oral hypoglycemic drug used in the treatment of type II diabetes has been 
extensively studied,154-168 and reported to exhibit polymorphism. Five polymorphs (IL, IH, and II-IV) 
of tolbutamide have been isolated and characterised, but while previous studies have focussed on 
the use of techniques such as DSC, XRPD, Infra red, solid state NMR and thermomicroscopy  in 
monitoring the polymorphic behaviour of tolbutamide, very few studies have employed the use of 
Raman spectroscopy and no previous study of polymorphism in tolbutamide using in situ Raman 
spectroscopy has been reported.
While Simmons et al.154 isolated two forms (A and B) of tolbutamide, Traue et al.160 and Burger155 
suggested the presence of four different polymorphs, I-IV. Simmons's forms A and B were found to 
be identical to Burger's forms I and III respectively.168
All four forms reported by Burger have been fully characterised; I, II and III from single crystal x-
ray data, while form IV was solved from conventional x-ray powder diffraction data.168
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In  2009,  Hasegawa et al.165 confirmed the existence of conformational polymorphism in form I of 
tolbutamide using DSC and XRPD. Subsequently Burger's form I was renamed IL while its 
conformer was named IH. Form IL transforms to form IH at 38°C upon heating.167 Also forms II, III 
and IV have been reported to transform into form IH at 100°C, 106°C and 88°C respectively when 
heated.167,168, while form IV also transforms into form II at 80°C.168
Thirunahari et al., confirmed  the melting points of both forms IH and II as 128°C and 117°C 
respectively.167
The main objective of this study therefore, is to carry out a novel study of the polymorphic 
transformations obtainable from amorphous tolbutamide using the constrained crystallisation 
approach (slow heating of the amorphous form), monitoring the observed transitions using  in situ 
Raman spectroscopy complemented with VTXRPD and DSC.
 
                                  Figure 5.1: Molecular structure of tolbutamide
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5.3   Experimental
5.3.1   Materials
Tolbutamide was purchased from Sigma-Aldrich Dorset UK was used in all experiment as received. 
The as-received sample was shown by comparison of the XRPD pattern with the reported crystal 
structure of Hasegawa et al.165 to be form IL.
5.3.2   DSC 
A Q2000 series differential scanning calorimeter, manufactured by TA Instrument, Crawley, 
England, was used for the DSC analysis. Approximately 4mg of tolbutamide was first heated at 
10°C/minute to 145°C, cooled down to -40°C at 10°C/minute before subsequently heating the 
supercooled sample slowly at a heating rate of 1°C/minute back to 145°C (modulating the 
temperature for 60 seconds every degree.
5.3.3   XRPD
XRPD patterns were collected on a Bruker D8 diffractometer system (Bruker AXS, Madison, WI, 
USA), operating in a Debye-Scherrer geometry, at a wavelength (λ) of 1.54059Å, 40kV voltage, 
and a current of 40mA, using a LynxEye detector. The sample was heated using a Cryostream plus 
controller (Oxford Cryostreams Ltd. Hanborough Oxford OX29 8LN) at 3OC/minute from -20°C to 
151°C and patterns were collected at each temperature step (overall accumulation time of 8 minutes) 
at a scan time of 0.3 second.
5.3.4   Raman
Raman spectra were collected using a confocal Horiba-Jobin-Yvon LabRAM system (Horiba-Jobin-
Yvon Ltd Middlesex U.K.), using a 600 lines/mm grating and a 785 nm excitation laser. A Synapse 
CCD detector was employed. Temperature control was achieved using a Linkam hot-stage (Linkam 
Scientific Instrument Ltd, Surrey U.K). 
The tolbutamide sample was first heated to 145°C, held at this temperature for 2 minutes and 
quenched on a surface that had been pre-cooled to -100°C with liquid nitrogen. 
The super-cooled sample was then heated at stepwise 1°C/ minute intervals, and were held at 
temperature during data collection (typically 10–20 seconds maximum). Data sets were collected 
every 1°C. Sample, approximately 1 mg was placed on a microscope slide without a cover slip.
5.3.5   Data Analysis
The Raman spectra obtained were subjected to PCA analysis using 'PCA packages' within the 'R' 
programming suite. Raw spectra (variance-scaled and mean-centred before analysis) were used, the 
phonon spectra range/mode (30-400cm-1) and molecular fingerprint range/mode region (500-
2000cm-1) were used for the analysis.
The most important principal components (PCs) were determined from percentage variance plots 
and were used to investigate trends in the spectra features of the Raman data. PC1, PC2 and PC3 
were selected, they accounted for over 90% variance.
82
5.4   Results and Discussion
5.4.1   Confocal Raman spectroscopy
The in situ Raman spectra of the slow heating of the amorphous solid sample of tolbutamide is 
shown in figure 5.2 below (intensities are in colours, PC1 is black, PC2 red, PC3 blue.): 
                                Figure 5.2: Variations in the Raman spectra (top right), PC1, PC2 (top left) with 
                  temperature and loadings (bottom), for the slow heating of      
                            amorphous tolbutamide
Visual inspection clearly shows transformations occurring has the sample is been heated from the 
initial amorphous phase until it starts to melt (non-abruptly) around 128°C, which is in agreement 
with previously published results.167,168
Regions within the experimental spectra window that show prominent changes in the figure above 
include the phonon-mode (20-350 cm-1), and also in molecular-mode region i.e. 780-850cm-1, 1120-
1190cm-1 and 1580-1620cm-1 respectively.
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To further show the transformations occurring as the in situ experiment progresses and to efficiently 
reduce the effect of data complexity, principal component analysis was deployed,169 figures 5.3-5-6 
below (and overleaf) show plots of the changes in the Raman spectra (Raman shift) as function of 
both the principal components and temperature for four different regions of the spectral window 
earlier mentioned (with the corresponding peaks assigned170).
            Figure 5.3: Variations in the Raman spectra (top right), PC1, PC2 (top left) with      
       temperature and loadings (bottom), for the low wave number bands (20-340cm-1) 
                              
The figure above shows the changes in the low wave number or phonon-mode bands as the heating 
progresses, these bands due to lattice vibrational modes (this region provides useful information 
about lattice environment), this is the first time that these data have been presented for this system.
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                     Figure 5.4: Variations in the Raman spectra (top right), PC1, PC2 (top left) with      
          temperature and loadings (bottom), due to the O=N-C stretching vibrations 
                                 (780-825cm-1)                      
Similarly, figure 5.4 shows the changes in the stretching vibrations due to the O=N-C bond in the 
molecule as the transition progresses.
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         While figure 5.5 below shows the changes in the symmetric phenyl breathing mode (1120-
1190cm-1) during the course of the experiment.
                                 
                   Figure 5.5: Variations in the Raman spectra (top right), PC1, PC2 (top left) with 
                 temperature and loadings (bottom),for the symmetric phenyl             
                                       breathing mode (1120-1190cm-1)  
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                   Figure 5.6: Variations in the Raman spectra (top right), PC1, PC2 (top left)  
                                       with temperature and loadings (bottom), for the symmetric  
                                        C=C stretching vibrations (1580-1620cm-1)  
Figure 5.6 above also shows the variations in the C=C stretching vibrations in the molecule during 
the experiment.
In summary therefore, the constrained crystallisation approach monitored  using in situ Raman 
spectroscopy has allowed a very rapid screen of this known polymorphic system, uncovering a very 
rich behaviour.
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5.4.2   X-ray powder diffraction
The x-ray powder patterns obtained from the heating of amorphous sample of tolbutamide is shown 
in figure 5.7 below (using principal component analysis, PC1 is black, PC2 red, PC3 blue and PC4 
is green) : indicating the following transitions, amorphous→form IV→form II→form IL (patterns 
compared with those published by Kimura et al.)168
                                  Figure 5.7: Variations in patterns (top right), PC1, PC2 (top left) with      
                              temperature and loadings (bottom), for the VTXRPD experiment 
Visual inspection of figure 5.7 clearly shows the transformations as the amorphous sample is being 
heated, with the transitions being more apparent than in the earlier discussed Raman experiment 
(expected given XRPD probes crystalline order and Raman probes molecular vibrations in general). 
With the sample eventually melting at temperature expected from literature (128°C)168 and also in 
agreement with results obtained from the Raman experiment above.
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Although it is worth mentioning that the temperature of transformation between the different forms 
are lower in the VTXRPD experiment as compared with the in situ Raman analysis, this is likely 
due to larger sample volume (used in the VTXRPD) and therefore greater opportunities for new 
phases to nucleate.
Also the experimental set up used for XRPD analysis encouraged the formation of ice on the 
capillary tube used, hence the appearance of ice peaks in figure 5.7 at low temperature. Longer 
experiment can be used to remedy this resulting in lower temperature resolution.
Conclusion
We report for the first time the monitoring of polymorphic transformations in tolbutamide using in 
situ confocal Raman spectroscopy (using the constrained crystallisation approach), the results 
deduced from the Raman spectroscopic analysis of the experiments comparing favourably well with 
those obtained from traditional methods (DSC and XRPD) used to characterise polymorphic 
systems.
As with the previous chapter, we were able to monitor the temperature dependence of the transitions 
using Raman spectroscopy.
The in situ study described above is easy, fast and automated. Very small amounts of sample is 
required and the results obtained provides molecular and solid-state information which is very 
useful in structural elucidation.
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6.0   Polymorphism in Imipramine Hydrochloride
6.1   Polymorphic fingerprinting using phonon-mode Raman  
spectroscopy
Abstract
We report for the first time the existence of polymorphism in the antidepressant drug imipramine 
hydrochloride. Using constrained crystallisation from the amorphous solid state to kinetically trap 
polymorphs via Oswald's rule of stages ( this approach has proved highly effective in our previous 
chapters), two new polymorphs of imipramine hydrochloride were uncovered in our first attempt at 
screening, using in-situ Raman spectroscopy/microscopy.
The as-received form is therefore labelled form I, with form II being that which crystallises directly 
from the melt and form III crystallising from form II. Our results was supported by additional 
analysis using Variable Temperature X-ray Powder Diffraction (VTXRPD) and thermal studies 
using Differential Scanning Calorimetry (DSC).
Patterns from the VTXRPD experiment showed two transformations at 69°C and 75°C (the as 
received) via an intermediate at 30°C (mixture of amorphous and crystalline). While the DSC data 
obtained suggests the presence of at least two polymorphs: a low melting form (melting point at 
~161.65°C ) and a high melting form, with a melting point around 173.3°C respectively. 
Principal Component analysis (PCA), was used to further explain the trends observed in data 
obtained from the Raman in situ experiment. This analysis affords a quick overview and 
identification followed by a more detailed appraisal.
6.2   Introduction
In this study, Imipramine hydrochloride was selected as a test case: no polymorphism has been 
reported to date for this system, and a single crystal structure of the known (commercially available) 
form has been previously determined.171
Imipramine is a tricyclic antidepressant, formulated as the hydrochloride (figure 6.1 overleaf) salt to 
enhance solubility. By slowly heating the amorphous solid form (monitored using Raman 
spectroscopy) of imipramine hydrochloride we were able to kinetically trap its polymorphs via the 
Oswald's rule of stages.21,172 
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                      Figure 6.1: Molecular structure of imipramine hydrochloride
A previous publication173 involving mechanical energy calculations and molecular dynamics 
simulations showed that the side chain folds above one of the phenyl rings, two different side chain 
conformations were obtained during the simulations in vacuo. Their results also concluded that 
tricyclic antidepressant such as imipramine hydrochloride have flexible molecules which readily 
may cross energy barriers between different conformations. The above findings was a major reason 
for choosing imipramine hydrochloride for this study.
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6.3   Experimental
6.3.1   Materials
Imipramine hydrochloride was purchased from Sigma-Aldrich Dorset UK was used in all 
experiment as received.
6.3.2   DSC 
A Q2000 series differential scanning calorimeter, manufactured by TA Instrument, Crawley, 
England, was used for the DSC analysis. Approximately 4mg of imipramine hydrochloride was first 
heated at 10°C/minute to 185°C, cooled down to -40°C at 10°C/minute before subsequently heating 
the supercooled sample quickly at different heating rates of 1, 2, 5,10, 20, 25, 50, and 100°C/minute 
back to 200°C. This was done to investigate the effect of heating the amorphous material, the 
'quenching' approach allowed the amorphous form to be isolated.
6.3.3   XRPD
XRPD patterns were collected on a Bruker D8 diffractometer system (Bruker AXS, Madison, WI, 
USA), operating in a Debye-Scherrer geometry, at a wavelength (λ) of 1.54059Å, 40kV voltage, 
and a current of 40mA, using a LynxEye detector. The sample was heated using a Cryostream plus 
controller (Oxford Cryostreams Ltd. Hanborough Oxford OX29 8LN) at 3°C/minute from -10°C to 
151°C and patterns were collected at each temperature step (overall accumulation time of 8 minutes) 
at a scan time of 0.3 second.
6.3.4   Raman
Raman spectra were collected using a confocal Horiba-Jobin-Yvon LabRAM system (Horiba-Jobin-
Yvon Ltd Middlesex U.K.), using a 600 lines/mm grating and a 785 nm excitation laser. A Synapse 
CCD detector was employed. Temperature control was achieved using a Linkam hot-stage (Linkam 
Scientific Instrument Ltd, Surrey U.K). 
The imipramine hydrochloride sample was first heated to 185°C, held at this temperature for 2 
minutes and quenched on a surface that had been pre-cooled to -100°C with liquid nitrogen. 
The super-cooled sample was then heated at stepwise 1°C/ minute intervals, and were held at 
temperature during data collection (typically 10–20 seconds maximum). Data sets were collected 
every 1°C. Sample, approximately 1 mg was contained between a glass microscope slide and cover 
slip, to allow the amorphous form to be isolated.
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6.3.5   Data Analysis
The Raman spectra obtained were subjected to PCA analysis using 'PCA packages' within the 'R' 
programming suite. Raw spectra  (variance-scaled and mean-centred before analysis) were used, the 
phonon spectra range/mode (30-400cm-1) and molecular fingerprint range/mode region (500-
2000cm-1) were used for the analysis. The splitting of the data into these two ranges was to allow for 
a better comparison of the phonon-mode region with the conventional fingerprint region, thus 
showing the usefulness of the former, which is being emphasised in this study.
The most important principal components (PCs) were determined from percentage variance plots 
and were used to investigate trends in the spectra features of the Raman data. PC1, PC2 and PC3 
were selected as they accounted for over 99% variance.
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6.4   Results and Discussion
6.4.1   DSC analysis
Figure 6.2: DSC plot obtained from the heating of the supercooled melt of imipramine HCl     
at different temperature; 1, 2, 5, 10, 20, 25, 50 100°C/minutes (Key: Tg → glass transition 
temperature, R → recrystallisation peak, Tm → melting temperature: while a  is the first melting 
and b is the second melting)
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Figure 6.2 overleaf shows the DSC trace obtained from heating the super-cooled melt of 
imipramine hydrochloride at different temperature; 1, 2, 5, 10, 20, 25, 50 100°C/minutes, clearly 
suggesting that two polymorphs can be obtained from the melt using different heating rates (as 
shown in fig. 6.2, with two melting temperature/points (at intermediate heating rates of 10, 20 and 
25°C respectively), thus indicating the existence of polymorphism in the compound, which was 
previously unreported. The isolation of the glass transition temperature in the experiment (not very 
clear at 1 and 2°C heating rates) indicated that the amorphous form of imipramine hydrochloride 
was obtained prior to heating. It is also interesting to note that the recrystallisation peak shifts as the 
heating rate changes, appearing at higher temperature as the heating rate increases.  
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6.4.2   Confocal Raman spectroscopy
The in situ Raman spectra of the slow heating of the amorphous solid sample of imipramine 
hydrochloride is shown in figure 6.3 below i.e. the phonon-mode region only (intensities is in 
colours, PC1 is black, PC2 red):  
Simple visual inspection of figure 6.3 suggests three separate events during the experiment, but 
more detailed analysis (with PCA) revealed the following transitions: amorphous→ form I (60°C) 
→form II (74°C) →form III (98°C) after which the sample melts around 173°C.
     Figure 6.3: In situ Raman spectra of imipramine hydrochloride (phonon-mode region only)
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The principal component projections of the Raman data obtained from the in situ experiment further 
elaborates the changes that occur as the solid amorphous form of imipramine hydrochloride is being 
slowly heated: Figure 6.4 below below shows a plot of the changes in the Raman spectra (Raman 
shift) as function of both the principal components and temperature.
                                Figure 6.4: Variations in the Raman spectra (top right), PC1, PC2 (top left) with 
                  temperature and loadings (bottom), for the slow heating of      
                            amorphous imipramine hydrochloride   
Two principal components (PC1, black and PC2, red) were chosen for the analysis because they 
accounted for over 99% of the variance. The temperature of transitions (see left hand side of 
picture) is in agreement with those obtained in figure 7.3, i.e. 60, 74 and 98°C respectively. With the 
transitions taking place in single steps at the aforementioned temperature. 
With the major spectral changes occurring between 100 and 200cm-1 (see lower panel), which 
further shows the usefulness of the phonon-mode region in distinguishing polymorphic changes. 
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Figures 6.5a below and 6.5b overleaf shows the changes in the C-N stretching vibration and the 
phenyl breathing mode (due to multiple substitution) as the imipramine hydrochloride is being 
heated.
              Figure 6.5a: Raman spectra showing changes in the C-N stretching vibration
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               Figure 6.5b: Raman spectra showing changes in the phenyl breathing mode
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Figures 6.5c and 6.5d shows the representative phonon-mode and molecular-mode Raman spectra
obtained from the slow heating experiment using imipramine hydrochloride respectively:
                   Figure 6.5c: Phonon-mode Raman spectra of imipramine hydrochloride
                  Figure 6.5d: Molecular-mode Raman spectra of imipramine hydrochloride
99
While the phonon peaks are different and easily distinguishable (figure 6.5c), the molecular modes 
appear similar as depicted in figure 6.5d, thus making it easier to differentiate among the various 
forms of imipramine hydrochloride using the phonon-mode spectra by visual inspection.
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The change in peak position and peak width (using a Gaussian fit) of the phenyl ring deformation 
stretching vibration at approximately 684cm-1 (this peak was chosen because of its high intensity) on 
heating across the transition is reported in figures 6.6a and 6.6b respectively (below): Thus showing 
the temperature dependence of the data obtained from the in situ Raman experiment.
                             Figure 6.6a: Plot of peak position as a function of temperature
                              Figure 6.6b: Plot of peak width as a function of temperature
The peak widths in the amorphous state are wider than in the crystalline state due to the (static) 
disorder of the molecule.
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6.4.3   X-ray powder diffraction
Principal component projection was also deployed to validate the transformation observed in the 
variable temperature XRPD experiment as shown in figure 6.7 below: 
                                Figure 6.7:  Variations in the X-ray patterns (top right), PC1, PC2 (top left) with 
                   temperature and loadings (bottom), for the slow heating of      
                            amorphous imipramine hydrochloride   
Three principal components (PC1, black, PC2, red and PC3, green ) were chosen for the analysis 
because they accounted for over 99% of the variance. Two major changes occurred during the 
heating experiment i.e. at 70°C and 118°C respectively, and while the first transition was in a step 
and sudden, the second transformation was multifarious and complex. The VTXRPD experiment 
was slower than the Raman analysis but has the potential of providing crystallographic information 
including crystal structures. The changes in x-ray patterns as the heating progressed clearly supports 
our findings using Raman spectroscopy. While the multi-facet nature of the second transition in fig. 
6.7 is a pointer to the fact that more than one possible transformation can be obtained from heating 
the amorphous form of imipramine hydrochloride.
Although the temperature of transition observed with the XRPD is higher than that obtained from 
the Raman analysis, comparing the latter with the former allows us to be sure that the changes we 
see in the Raman are indeed due to polymorphic transformations.
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Conclusion
In conclusion, we demonstrate that screening of pharmaceutical compounds for polymorphism can 
be rapidly achieved for milligram quantities of material using in situ phonon-mode Raman 
spectroscopy, and demonstrate that phonon-mode confocal Raman spectroscopy/microscopy 
(coupled with hot-stage microscopy)  has the potential to offer a simple, reliable and rapid method 
of screening for polymorphism in pharmaceutical materials. With the results obtained from the 
Raman analysis comparing favourably well with both DSC and XRPD techniques in confirming 
that imipramine hydrochloride exhibits polymorphism (not previously reported prior to this study).
Data analysis is relatively straightforward, with visual inspection of the phonon-mode spectra 
sufficient to distinguish between the different polymorphs of imipramine hydrochloride. The 
deployment of principal component analysis in this study also makes it easier and quicker to 
identify transitions and the spectral changes (and therefore molecular) changes which under pin 
them. 
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7.0   Raman spectroscopy: Backscattering versus 
transmission geometries
7.1   Transmission Raman spectroscopy as a tool for quantifying  
polymorphic content of  pharmaceutical formulations  
Abstract
We present the first quantitative study of polymorphic content in a model pharmaceutical 
formulation using transmission Raman spectroscopy (TRS), and compare the results obtained with 
those from traditional backscattering geometry. The transmission method is shown to provide a true 
bulk measurement of the composition, being unaffected by systematic or stochastic sub-sampling 
issues that can plague traditional backscattering geometries. The accuracy of the quantification of 
the polymorphs using TRS was shown to surpass considerably that achieved using conventional 
backscattering mode.
For a model-free fit, the TRS method yielded R2 of 0.996 compared to the backscattering value of 
0.802; for a partial least squares fit with a single component the TRS method accounted for 98.09% 
of the variance in the data and yielded an R2 of 0.985, compared to 89.65% of the variance and R2 
of 0.804 for the backscattering method.
7.2   Introduction
A number of analytical applications within the pharmaceutical production environment require a 
rapid, non-invasive and, most importantly, a non-destructive method for the assay of the bulk 
content of pharmaceutical formulations. In recent work, previously unexploited properties of 
transmission Raman spectroscopy were reported.35,174 These include the provision of volumetric 
information on the sample content through the removal of sub-sampling and suppression of 
interfering surface layer Raman and fluorescence signals that are particularly beneficial for rapid 
probing of pharmaceutical capsules and coated tablets. This development stimulated new research 
in this area, paving the way for the establishment of a new analytical technique well suited to a 
number of problems faced by the pharmaceutical industry.
Although conventional backscattering Raman spectroscopy has been used in pharmaceutical 
applications extensively,175-183 it suffers from sub-sampling (limited lateral interaction area and 
limited penetration depth) when applied to assessing the bulk content of typically highly 
heterogeneous formulations. This severely restricts technique’s predictive power. These 
conventional studies also exploited the capability of conventional Raman to ascertain the 
polymorphic content of pharmaceutical formulations.184
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The issue of limited lateral size of the interaction zone was addressed by expanding the laser 
deposition and Raman collection areas to several millimetres in the backscattering geometry.185
 Although this approach eliminated the sub-sampling problem in lateral dimensions, the restricted 
penetration depth still remained an issue associated with over-sensitivity of the technique to signals 
originating from the surface layers of sample; e.g. fluorescence or Raman signals originating from 
the coating or capsule shell.
The limited penetration depth issue was effectively addressed by the recent advent of transmission 
Raman methodology into pharmaceutical arena. In the transmission Raman geometry, the laser 
beam is incident upon one side of the probed capsule and the Raman light is collected from the 
opposite side. 
This mode of operation stems from the development of non-invasive methods such as Spatially 
Offset Raman Spectroscopy (SORS186,187) or deep probing of diffusely scattering samples.188-191 The 
transmission Raman spectroscopy (TRS) concept can be considered to be a special case of SORS 
with the illumination and collection points displaced to the extreme and as such it shares some 
common characteristics with SORS. 
Although the transmission Raman technique was demonstrated in the early days of Raman 
spectroscopy,192 its benefits for the non-invasive probing of the bulk content of pharmaceutical 
samples had not been previously recognised or exploited. In addition to the elimination of the sub-
sampling problem the technique also effectively suppresses both fluorescence and Raman 
components emanating from coating or capsule layers.35 Although some sensitivity to the depth of 
probed layer within sample remains in transmission geometry it is drastically weaker than that 
associated with the conventional backscattering geometries.174
In recent research, Johansson et al.178 established the ability of the transmission Raman technique to 
provide quantitative information on the binary mixture content of capsules and tablets. In this study, 
20 test tablets and an unspecified number of capsules specifically formulated were used. The study 
achieved a relative root mean square error of prediction for Active Pharmaceutical Ingredient (API) 
concentration of 2.2% and 3.6%, respectively, with a 5s acquisition time. The investigation also 
demonstrated the robustness of the calibration model, which provided satisfactory prediction 
accuracy for a relatively low number of calibration points (only three).
A similar study was performed by Eliasson et al.,193 using transmission Raman spectroscopy on 
production relevant formulations prepared in a laboratory environment. White development 
capsules were used and these presented interference that hampered the use of other process 
analytical technology compatible optical spectroscopic methods, such as NIR absorption and 
conventional Raman spectroscopy. These signals were effectively suppressed (by a factor of 30) by 
the transmission Raman approach.
The study was performed on 150 capsules and the measured relative root mean square error of API 
prediction (1.2% for a 5s acquisition time). Here we present the first quantitative measurement of 
polymorphs (identical chemicals of different crystalline forms) in pharmaceutical formulations 
using TRS and compare its performance with conventional backscattering Raman spectroscopy.
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Flufenamic acid, a non-steroidal anti-inflammatory drug, was chosen as a model polymorphic 
system. It has been reported to adopt up to 10 polymorphs.80 Forms I and III were chosen for this 
work, as they are readily obtained, are both kinetically stable under standard laboratory conditions, 
and are well characterised with known crystal structures.87,91 
The molecules adopt slightly different conformations in the two polymorphs, which differ primarily 
in the relative orientation of the phenyl groups about the secondary amine, with dihedral angles of 
42.9 between planes defined by the two phenyl rings in form III (CSD reference FPAMCA), and 
53.2 in form I (CSD reference FPAMCA11). In both forms, the molecules are coupled into dimers 
which are linked by the hydrogen-bonded carboxylic acid groups. 
An intra-molecular N–H-----O=C hydrogen bond is formed in both forms. 
The molecular Raman bands are therefore expected to be rather similar. The packing of the different 
molecules is significantly different in the two forms, and therefore any Raman bands which are 
sensitive to intermolecular interactions are expected to be strongly different between the two forms.2 
This conformational polymorphism is common in pharmaceutical solids.194
Flufenamic acid is therefore a typical, industrially relevant (partially) conformational polymorphic 
compound which forms an excellent model system for this study.
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7.3   Experimental
7.3.1   Materials
Flufenamic acid was purchased from Sigma-Aldrich Dorset UK. Both forms were characterised 
using transmission X-ray powder diffraction (XRPD) and differential scanning calorimetry (DSC) 
in addition to transmission and backscattering Raman spectroscopy. The as-received sample was 
shown by comparison of the XRPD pattern with the reported crystal structure of Krishna Murthy et. 
al.87 to be form I.
This material was therefore used as the stock sample of form I. Pure form III was prepared by 
simple evaporative crystallisation from propanol and identified by comparison of the XRPD pattern 
with the reported crystal structure of McConnell.91 From the XRPD, DSC and Raman spectroscopy, 
both forms I and III are estimated to have polymorphic and chemical purity in excess of 99%. 
Mixed samples of total individual mass of 1g were prepared by weighing suitable amounts of 
sample to an accuracy of 0.0001g and co-milling forms I and III in a ball mill (Retsch MM400) for 
60 seconds. 
A total of 27 samples of compositions 0.01, 0.02.0.09, 0.1, 0.2.0.8, 0.9, 0.91.0.98, and 0.99 (mole 
fraction) were prepared. XRPD and differential scanning calorimetry (DSC) were used on a sub-set 
of samples to confirm that no detectable (1%) transformation I / III or III / I occurs under these 
conditions. Visual inspection of the Raman data from both transmission and reflection is also in 
accord with no detectable polymorphic transformation under these conditions.
7.3.2   Instrumental
The transmission Raman spectra were measured using a Cobalt Light System Ltd TRS100 
transmission Raman optical engine. The probe beam was generated using a frequency stabilised 
diode laser operating at 830 nm. The laser power at the sample was ~800 mW and the laser spot 
diameter ~3 to 4 mm at the sample. The sample was placed at one side of the holder and the laser 
directed through the sample and collected at 180° from the direction of the laser light.
The spectra are not corrected for the variation of the detection sensitivity across the spectral range. 
The spectral resolution was estimated to be 5–6 cm-1. Measurement parameters were 10s (10 
acquisitions of 1s duration each averaged), unless otherwise stated.
The reflection Raman spectra were collected using a HORIBA Jobin Yvon Ltd LabRAM HR 
system, interfaced with an Olympus BX51 optical microscope. A laser wavelength of 785nm was 
employed and an objective lens of x50 magnification. The laser power was 300 mW and the laser 
spot diameter was approximately 1 micron. In order to reduce as far as possible any issues with sub-
sampling, the laser spot was scanned over a 50 x 50 micron2 area during data collection using the 
‘‘Duoscan’’ module supplied with the instrument. 
The Raman spectra were collected under confocal conditions. The sample was placed onto a glass 
microscope slide, and the laser directed onto the sample and collected in backscattering geometry. 
The spectrometer was calibrated using the Rayleigh scattering, the peak position of silicon (520.7 
cm-1), and the spline files provided by the manufacturer. All spectra were collected in the same day 
under the same conditions in order to minimise where possible any calibration issues due to 
instrumental thermal drift, etc.189
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The Raman light was collimated and dispersed by a 600 lines per mm grating, along a total beam 
path of 800 mm, with Raman spectra recorded using a Synapse CCD which was thermoelectrically 
cooled. Spectral resolution (i.e. typical peak width) is estimated to be mainly determined by the 
sample and of the order of 4 cm-1. 
The spectrum (30–2000 cm-1) was collected in several windows and merged into a single spectrum 
using the LabSpec software supplied with the instrument. Measurement parameters were 2 seconds 
per window unless otherwise stated.
7.3.3   Data processing
For the chemometric analyses both datasets were handled in exactly the same manner using a partial 
least squares routine as implemented by the ‘‘PLS’’ package195 within the ‘‘R’’ programming suite. 
Raw spectra were used, and the entire data range was used for both transmission and backscattering 
datasets. Kernel PLS was employed and included a multiplicative scatter correction.196 A ‘‘leave one 
out’’ validation procedure was applied (cross validation yielded essentially identical results). A 
single PLS component was found to be appropriate for both transmission and backscattering 
datasets.
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7.4   Results and discussion
7.4.1   Backscattering geometry
Data collected in backscattering geometry for the mixed samples are presented in figure 7.1. The 
spectra are of high quality with good signal : noise ratio. Visual inspection indicates some clear and
obvious differences between the two polymorphic forms of flufenamic acid.
The molecular bands (ca. 400–4000 cm-1) are approximately similar in intensity and position (as 
would be expected for two polymorphic samples which by definition contain the same molecules), 
but detailed differences emerge on closer inspection. The most obvious is the difference in position 
of the symmetric phenyl stretching mode, which occurs at 1003.8 cm-1 in form I and 995.1 cm-1 in 
form III.
Note that this particular peak is well-separated from other bands. In contrast to the molecular bands, 
the phonon-mode bands (ca. 30–400 cm-1) differ strongly between the two polymorphic forms. 
This is expected, as the phonon-mode bands are very sensitive to inter intermolecular interactions—
which are expected to be very different between the two forms—whereas the molecular bands are 
most sensitive to the intra-molecular interactions which are expected to be very similar.4
Figure 7.1: Raman spectra of polymorphic mixtures of FFA, collected in backscattering geometry, 
for entire spectral range (LHS). Composition (mole fraction of form I) is given at the right, spectra 
for 0.1, 0.5, and 0.9 are in bold. Signature peaks for forms I and III are labelled
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Considering the spectra for all compositions collected under backscattering geometry, it is clear 
(again from visual inspection of the data) that although, globally, the spectra change across the
series from form I to form III, this trend is not reproducible from one composition to another.
There is no locally smooth change in the spectra as a function of composition. Note in particular the 
two ‘‘fingerprint’’ peaks for forms I and III which are labelled in the figure. For example, the 
spectrum for 0.91 mole fraction of form I more closely resembles that for 0.8 rather than 0.9. Also, 
the backscattering spectra do not exhibit the expected symmetry around 0.5 mole fraction: far more 
spectra resemble form III than form I. 
There are therefore two issues with the backscattering data which render them unsuitable for any 
reliable and quantitative studies in this situation: firstly, there is some inherent variability in the 
data; and secondly, there is a strong over-representation of form III in the data for the mixed 
samples.
This latter issue is systematic, whereas the former is stochastic. We emphasise at this point, and will 
clearly demonstrate later, that these issues with the backscattered Raman spectra do not reflect any 
variability in the bulk composition of the samples but are inherent in the use of backscattering data 
to characterise this model pharmaceutical system.
7.4.2   Transmission geometry
Data collected in transmission geometry are presented in figure 7.2 (overleaf). The spectra for the 
pure forms are comparable with those collected in backscattering geometry which were fully 
discussed earlier, albeit at slightly lower spectral resolution (full width at half maximum of the 
phenyl peak 7cm-1 for transmission mode versus 4cm-1 for backscattering, data not shown). The 
primary difference between the backscattering and transmission data is for the mixed samples. A 
clear and obvious smooth variation in the spectra as a function of composition is readily apparent 
even from visual inspection of the data.
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Figure 7.2: Raman spectra of polymorphic mixtures of FFA, collected in transmission geometry, for 
entire spectral range (LHS) and phononmode bands (RHS). Composition (mole fraction of form I) 
is given at the right, spectra for 0.1, 0.5, and 0.9 samples are in bold. Signature peaks for forms I 
and III are labelled and the symmetric phenyl breathing mode is indicated with *.
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7.4.3   Chemometric analyses
The results of the chemometric analysis (partial least squares, PLS) for all 27 mixed samples are 
presented in figure 7.3. Analysis of the backscattering data clearly does not yield a wholly reliable 
model, in that the observed and predicted values are spread significantly from the expected straight 
line with gradient of one.
The single component PLS model in this case only explains 89.7% of the variance in the data. 
There also appears to be a systematic trend overlaid on the scattered data points, with form I being 
under-represented in the PLS model (many data points lie below the ideal straight line, indicating an 
under-estimation of the amount of form I). This is thought to arise from the previously noted over-
representation of form III in the raw spectra, and will be addressed below.
Figure 7.3: Results of PLS analysis (validation plot, all data) for transmission and backscattering 
       data
In contrast to the scatter observed in the backscattering data, analysis of the transmission data (also 
figure 4.4) yields a highly satisfactory model, with the points correlating well with the expected 
straight line. In this case the single component model explains 98.09% of the variance in the data, 
and yields a linear regression R2 of 0.985.
A PLS analysis was also performed employing data in the spectral windows below 500 cm-1, in 
order to investigate whether the increased variance of the spectra in the region below 500 cm-1 
(compared to above 500 cm-1) would produce a more robust model than the one described above, 
which employed the entire spectral range. The amount of variance modelled increased from 98.09% 
(entire range) to 99.4% (below 500 cm-1 only), i.e. the use of only the data below 500 cm-1 further 
improves the robustness of our model.
For the transmission data, but not the backscattering, the agreement between observed and 
calculated is very satisfactory, and demonstrates for the first time that TRS data are suitable for 
quantitative chemometric analysis of polymorphic mixtures.
The fit of the chemometric model to the TRS data is pleasing, however, the model constructed 
required input of all 27 experimental datasets, i.e. the model was constructed from the experimental 
data. In order to fully validate the use of TRS data for quantitative analysis of polymorphic 
mixtures, a model-free approach analysis (with less potential for possible or potential bias) has also 
been performed to further investigate the validity of using TRS data for polymorphic quantification.
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7.4.4   Model-free analysis
For a model-free comparison of the relative merits of transmission and backscattering Raman 
spectra for quantitative analysis of polymorphic mixtures, we have employed the average position 
of the phenyl breathing mode peak which arises from the two overlapping peaks from the two 
polymorphic forms at ca. 1000 cm-1 as an approximation of the composition. 
It is expected to vary in a linear manner with composition. The averaged position of these two peaks 
was determined by fitting a single Gaussian function (plus single-parameter background); this peak 
was selected as it is very intense and the position is significantly different for the two polymorphs, 
as well as the lack of overlap with neighbouring peaks.
The peak position was chosen as this should be unaffected by sample preparation, Raman scattering 
cross-sections for the two polymorphs, etc., unlike perhaps the peak intensity. Results for this 
simple modelfree analysis are presented in figure 7.4.
Figure 7.4: Results of fitting the two symmetric breathing bands of the phenyl rings in forms I and 
      III with a single Gaussian
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Absolute peak positions vary systematically between backscattering and transmission experiments 
by approximately a wave number due to instrumental effects, vagaries of calibration, etc.; this is 
well within the expected range.189 
It can be seen that for the transmission data, the averaged position of the two phenyl peaks varies 
very smoothly in a linear manner as a function of sample composition (R2 = 0.996). In contrast, for 
the backscattering data the peak positions are extremely scattered (R2 = 0.802), and there is a clear 
over-representation of form III (under-representation of form I).
The scatter of the data points and the over-representation of form III are exactly the same issues that 
became apparent upon initial, visual inspection of the backscattering data and on performing the 
PLS analysis of the same. Overall, this model-free comparative study has strongly validated the 
PLS analysis of the TRS data, and has again highlighted some problems with the use of 
backscattering Raman data for quantitative analysis, at least in the current case.
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7.4.5   Data pre-treatment approach
To further test the robustness of the PLS model for the transmission data, the raw data from both the 
transmission and backscattering experiments were subjected to different sorts of data pre-treatment 
before generating the plots of the predicted versus the actual weights of form I in all the 27 samples 
prepared for the study, i.e. switching mean-centring off and leaving esd normalisation on (figure 
7.5a and 7.5b), switching mean-centring on and leaving esd normalisation off (figure 7.6a and 7.6b) 
and leaving both mean-centring and esd normalisation off (figure 7.7a and 7.7b).
In all cases (below and overleaf), the plots for the transmission data showed a better correlation 
between the predicted and the actual weights of form I in all the samples used.
Figure 7.5a:  Results of PLS analysis                         Figure 7.5b:  Results of PLS analysis
(validation plot, all data) for backscattering data       (validation plot, all data) for transmission data
(mean-centring off and esd normalisation on)            (mean-centring off and esd normalisation on)
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Figure 7.6a:  Results of PLS analysis                         Figure 7.6b:  Results of PLS analysis
(validation plot, all data) for backscattering data       (validation plot, all data) for transmission data
(mean-centring on and esd normalisation off)            (mean-centring on and esd normalisation off)
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Figure 7.7a:  Results of PLS analysis                         Figure 7.7b:  Results of PLS analysis
(validation plot, all data) for backscattering data       (validation plot, all data) for transmission data
(mean-centring off and esd normalisation off)            (mean-centring off and esd normalisation off)
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7.4.6   Issues with the use of backscattering data 
We therefore now turn to consider the two issues which render the backscattering data unsuitable 
for quantitative analysis of the composition of the mixture, namely the large scatter in the raw data, 
and the systematic over-representation of form III (and under-representation of form I) which was 
clearly observed in both the chemometric and model-free analyses.
The likely cause of the variability of the backscattering spectra is a lack of true averaging of the 
sample, i.e. a sub-sampling issue. As outlined earlier this is a well-known issue in the use of 
traditional backscattering Raman spectroscopy. To investigate the possibility of this sub-sampling 
problem, a series of 20 spectra were recorded on different areas of form I, form III and the 50 : 50 
mixture. 
The peak position of the symmetric phenyl breathing mode around 1000 cm-1, which is significantly 
different for form I and form III, was measured for each spectrum, and a standard deviation (i.e. 
reproducibility) for the position of this peak in the different samples was calculated. For mixtures 
with sub-sampling problems the reproducibility is expected to be lower and the standard deviation 
higher than for samples without this issue. 
Results were as follows: form I, 1.169; 50 : 50, 2.274; and form III, 0.253 cm-1. The higher standard 
deviation for the 50 : 50 mix compared to the pure forms clearly indicates the presence of some sub-
sampling problems. We can therefore conclude that the use of a Raman microscope in 
backscattering geometry, and the associated small sample volume, is not appropriate for accurately 
measuring the composition of bulk samples, even when great care is taken to reduce lateral sub-
sampling problems as far as possible by co-milling samples prior to measurement to encourage 
thorough sample mixing, and also by rastering the laser over a 50 x 50 micron2 area during the 
measurement. 
The sub-sampling problem explains the variability in the spectra, but not the systematic trend in 
which more spectra resemble form III than form I. In backscattering geometry, Raman spectroscopy 
is to some extent a surface technique. This systematic over-sampling of form III is suggestive of 
some type of surface segregation of the mixed samples, driven for example by different size 
reduction behaviours of the two polymorphs during milling, different surface energies of the 
polymorphs, etc., coupled with a limited penetration depth in the backscattering geometry.
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In order to probe the possibility of surface segregation during the sample preparation a series of 
scanning electron microscope (SEM) images were collected. Figure 7.8 shows the images for forms 
I, III (unmilled) and the 50 : 50 sample (after a minute of milling), taken after identical sample 
preparation to that employed in the Raman measurements. 
Figure 7.8: Scanning electron micrographs of: (a) FFA I; (b) FFA III; and (c) 50 : 50 mixture milled 
for 60 seconds. Scale bars are 500, 500 and 200 microns respectively
The particles of forms I and III exhibit very different external morphologies: form I is present as 
lozenge-shaped particles, whereas form III has a less isotropic, more sawdust-like appearance. In 
the image of the 50 : 50 mixed sample, the larger particles more closely resemble those of form I 
than form III, with the smaller particles resembling form III rather than form I. It is clear that co-
milling leads to a greater size reduction of form III than form I.
There are a number of ways in which this could affect the spectra of the mixed samples. A surface 
layer of form III on form I could lead to the systematic over-representation of form III. Likewise, a 
more efficient powder packing of III and resultant higher bulk density would also lead to this 
phenomenon. Regardless of the underlying cause of the over-representation of form III, in the 
backscattering Raman microscopy experiments strong evidence of sub-sampling problems is 
apparent, despite the careful sample preparation (co-milling) and data collection (laser spot 
rastering) designed to minimise these issues.
Sub-sampling occurs both laterally and vertically, and ultimately means that the backscattering data 
are unsuitable for quantification of the model polymorphic mixtures studied here, with both 
systematic and stochastic problems apparent. 
In contrast, the TRS data appear to be completely unaffected by sub-sampling and offer a reliable 
method of quantitatively characterising polymorphic mixtures. It is likely that the results presented 
will be widely applicable, beyond the simple model system selected for study here.
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Conclusion
For the first time we have investigated the use of transmission Raman spectroscopy for the 
quantitative analysis of polymorphic mixtures. It is a rapid technique which provides a true bulk 
measurement and is unaffected by systematic or stochastic sub-sampling issues that can plague 
traditional backscattering geometries, as demonstrated clearly in the current study. 
Transmission Raman data are suitable for reliable, quantitative studies of polymorphic mixtures 
using either chemometric methods, or simple model-free peak position averages, and offer 
significant advantages over backscattering methods for bulk characterisation of polymorphs.
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General Conclusion
The use of Raman spectroscopy in monitoring pharmaceutical crystallisation (by adopting the 
constrained crystallisation approach) has been shown in this study to be extremely useful. It is fast, 
sample requirement are of the order of 1mg or less (with no sample preparation needed) and the 
whole process can be easily automated. Data obtained from the study has compared favourably well 
with other techniques such as DSC and XRPD and also with those previously published in 
literature. The phonon-mode spectral was particularly useful as it helps to easily distinguish 
between both amorphous and crystalline forms and also provided information about the lattice 
environment. Structural/molecular changes could also be easily monitored during the course of the 
experiments using Raman spectroscopy, this is not the case with other techniques used in this study 
e.g. DSC and XRPD. Although it must be mentioned that a typical Raman spectrometer is 
expensive. 
The deployment of principal component analysis in the study for data elucidation helped greatly in 
simplifying and interpreting the large data sets generated throughout the study.
The novel technique of transmission Raman spectroscopy was also used to carry out quantitative 
studies of a model pharmaceutical formulation and was found to provide a true bulk measurement 
of the compositions used.
Future Work 
Improve on the experimental set up used in the study so that individual isolation of different 
polymorphic forms can be achieved.
Isolate the new forms of imipramine hydrochloride discovered during the study, characterise them 
using XRPD, DSC and eventually solve their crystals structures. Carry out solubility/dissolution 
studies on them as well.
Also solve the crystal structure FFA form two from the XRPD pattern obtained in the study.
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APPENDICES
                      Figure A: In situ XRPD pattern from the heating of amorphous FFA III
Amorphous FFA III transforms back to form I at 66ºC via an intermediate (mixture of forms I and 
III, at 60ºC), before melting at a much lower temperature of 72ºC as shown above (figure A). These 
differences in behaviour can be adduced to experimental set up, likely causes include several 
separate areas of amorphous material, caused by entrapment of bubbles in the capillary tube when 
the FFA sample was melted. Slightly different thermal conditions in each part of the capillary, 
coupled with stochastic nature of nucleation makes things difficult.  
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Figure B: In situ XRPD pattern from the reheating of nifedipine form II (below), form II transforms 
via a mixture of both forms I and II (at 63ºC and 66ºC) to form I (69ºC).
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Figure C: DSC trace of the slow heating of amorphous tolbutamide: inset are the two weak       
       endothermic events at  at 102.3ºC and 117.9ºC  (below)
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